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Colorectal cancer (CRC) is the third most common cancer, causing more than 600,000 
deaths worldwide annually. Due to the involvement of complicated signaling pathways, 
epigenetic changes and genetic/genomic alterations, it is still challenging to develop effective 
treatments to reverse CRC progression. In order to facilitate developing new drugs for CRC 
treatment and revealing the mechanisms of CRC drug action at molecular level, we have 
constructed a computational CRC Platform (http://www.cbligand.org/CRC/), a domain-
specific chemogenomics knowledgebase.  
The CRC platform consists of four database modules, e.g. 762 CRC related genes and 
proteins, 411 known CRC drugs and chemicals, 168383 CRC related bioassays, and 269 
CRC pathways, as well as searching tools for multi-function retrieval. It is also featured with 
powerful cloud computation technologies and computational tools to expedite target 
identification, polypharmacology and drug synergy analysis for CRC research.  
We have also demonstrated the application of the CRC platform in the case studies: (1) 
computational exploration of FDA-approved CRC drugs for polypharmacology and drug 
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synergy analysis; (2) in silico target identification of small chemical molecules from natural 
products with anti-CRC bioactivity; and (3) target identification and experimental validation 
for our in-house compounds. CRC platform will not only enrich our knowledge of CRC 
target identification, polypharmacology analysis, and biomarkers investigation, but also 
enhance the CRC chemogenomics data sharing and information exchange globally, and assist 
new drug design discovery and development for CRC treatment.  
 
Keywords: colorectal cancer (CRC); chemogenomics database; cloud computation; target 
identification; polypharmacology; natural product; drug discovery. 
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1.0 INTRODUCTION 	  	  
1.1 COLORECTAL CANCER 	   	  	  
Colorectal cancer (CRC) is the third most common aggressive cancer causing more than 
600,000 deaths worldwide annually and incidence rate is increasing in developing countries 
[1].  According to the report, approximately 1 in 20 Americans will be diagnosed with colon 
or rectum cancer in their lifetime [2]. In 2014, the American Cancer Society estimated that 
136,830 individuals were newly diagnosed with colorectal cancer and 50,310 colorectal cancer 
deaths in United States [3]. Furthermore, the incidence and mortality rates range from 30% to 
40% higher among males than females overall. As usual, the incidence and death rates for 
colorectal cancer increase with age. The median age of male patients diagnosed of colon 
cancer is 69 and for female patients is 73, which is older than the median age of patients 
diagnosed of rectal cancer, 63 in men and 65 in women [4]. However, the rates increased by 
1.1% per year among men and women aged younger than 50 years since 2002. This trend was 
confined to tumors in the distal colon (1.3% annually) and rectum (1.8% annually) [3]. 	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1.2 RISKS AND PREVENTIVE FACTORS 
 
 
CRC is also known as colon cancer, rectal cancer or bowel cancer. Signs and symptoms 
of CRC may include a change in bowel habits, such as diarrhea, constipation, rectal bleeding, 
blood in the stool, weakness and fatigue, unexpected weight loss [5]. Many risk factors are 
associated to the development of CRC like age, male, family history, inflammatory bowel 
disease, obesity, diabetes, tobacco smoking, alcohol, and diet style such as high intake of red 
and processed meat less consumption of fiber (Figure 1) [1]. However, the attributable 
effects of diet on molecular subtypes of CRC are not yet completely clear [6]. People with the 
family history of CRC or with inflammatory bowel disease are more likely to develop CRC. 
According to the literature, infection with Helibobacter pylori and other potential infectious 
agents contribute to the increased risk of CRC [7]. Additionally, there are a number of case-
control studies that have shown different gastrointestinal (GI) microbial compositions in 
normal subjects versus adenoma- and CRC-affected patients [8]. Hence, it is reasonable to 
suggest that there is a potential association between compositions of GI microbiota and CRC 
epidemiology. 
 
It is estimated that the number of CRC cases will continue to increase dramatically from 
1.2 to 2.2 million worldwide; the increased cases from developing countries are accounting 
for 62% over the next two decades [9]. It is crucial to take some preventative measures to 
control CRC before the CRC rate increased. Population-based screening is to detect the CRC 
at early stage like colorectal neoplasms, amendable for curative treatment, and it is shown to 
be an efficient and cost-effective method [10]. Meanwhile, it has been proposed that 
consumption of unrefined grains, fish, and legumes as sources of protein, could lower CRC 
risks. As mentioned before, obesity, diabetes, physical inactivity, excessive alcohol intake 
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and smoking are all associated to increasing the risk. Therefore, it is a primary strategy to 
control these factors at population level.  
Table 1 Summary of risks and preventive factors of colorectal cancer 
 
Risk factors Preventative factors 
Family history +++ Large bowel endoscopy 
Inflammatory bowel disease ++ Hormone replacement therapy 
Diabetes + Aspirin 
Helicobacter pylori infection+ Statins 
Other infections + Fruit and vegetables 
Smoking + Cereal fiber and whole grain 
Excessive alcohol consumption+ Fish 
Obesity+ Dairy products 
Sedentary+ Physical activity 
High consumption of red and processed meat+  
 
Note: +++ means very strong risk, + + means strong risk, + means moderate risk. 
 
 
1.3 GENOMICS AND RELATED PATHWAYS OF COLORECTAL CANCER 
 	  
1.3.1 Genetic pathways of colorectal cancer  	  	  	  
Colorectal cancer contributed to cancer mortality and morbidity, and its distinction 
between the colon and the rectum is largely anatomical [11]. The molecular mechanisms of 
colorectal cancer are clinically important because they are related to the disease prognosis 
and potential treatment development [12]. Researches on the molecular pathogenesis and 
therapy response for colorectal cancer increase greatly during the past decades years 
including the identification of the molecular mechanisms, and genetic changes causing the 
hereditary forms of colorectal cancer [13]. Different molecular alterations contribute to the 
apparent heterogeneity of early-onset CRC and the subgroups can be distinguished with 
distinct histopathology and familial characteristics [14].  
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It is important to know that most of the CRC cases (70-85%) are sporadic and the 
patients without identifiable genetic risk factors [15]. The development of CRC from begin to 
malignant lesions is usually more than 10 years, and dysplastic adenomas are the most 
common form of premalignant precursor lesions [16]. The classical model of colorectal 
carcinogenesis for the adenoma-carcinoma sequence has been evolving since its original 
formulation, and it links genetic alterations and their order of introduction, to different stages 
in tumor development [17]. This model was reported to involve adenomatous polyposis coli 
(APC) gatekeeping mutations, which provides a selective growth advantage to a normal 
epithelial cell, allowing it to outgrow the cells that surround it and become a microscopic 
clone (Figure 1) [18]. The APC gene mutation will contribute to the slow growth of small 
adenoma representing the target lesion for prevention and intervention of colorectal cancer 
[19]. Alternatively, not only APC gene but also KRAS gene will lead to uncontrollable new 
clonal growth with the expansion of cell number. Interestingly, the number of cells with only 
APC gene mutation is smaller than with both mutations. With the expansion of cells, the 
mutations in genes increase like BRAF, PTEN, BAX, SMAD4/TGF-β and TP53. In the end, 
they generate a malignant tumor invading through the membrane and metastasize to lymph 
nodes [20]. These “driver” gene mutations are with chromosomal instability, i.e., changes in 
number of chromosomes and structural changes of the chromosomes. This classical model of 
adenoma-carcinoma sequence is also named Chromosomal Instability (CIN) pathway.  
In addition to this CIN pathway, around 10-15% of sporadic CRC cases are associated 
to the Microsatellite Instability (MSI) with the condition of genetic hyper mutability that 
results from impaired DNA mismatch repair (MMR). Cells with abnormally functioning 
MMR are more likely to accumulate mutations (insertion or deletions) in microsatellites 
located in DNA coding regions, generating frame shift mutations and subsequently leading to 
sporadic CRCs [21]. Another genetic pathway is serrated pathway, which is different from 
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the CIN and MSI pathways initiated through classical APC mutations. The name of this 
pathway is attributed to the morphologically serrated appearance of the precursor lesions 
highlighted by the presence of BRAF (protein kinase B-Raf) mutation and epigenetic 
silencing of genes involved in cell differentiation, DNA repair, and cell-cycle control [22, 23]. 
Most of the sporadic CRC cases with a lot of mutations combined these above-mentioned 
genetic pathways. Therefore, these pathways will cross talk with each other and modify these 
routes to the carcinogenesis, which will make the cancer development more complicated. 
 
 
Figure 1. The classical model of CRC development from polyp to cancer. The APC gene 
mutation will contribute to the slow growth of small adenoma representing the target lesion 
for prevention and intervention of colorectal cancer. With the expansion of cells, the 
mutations in genes increase like BRAF, PTEN, BAX, SMAD4/TGF-βT, and P53. In the end, 
they generate a malignant tumor invading through the membrane and metastasize to lymph 
nodes. The green color indicates low risk and the orange indicates high risk of colorectal 
cancer. 
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1.3.2 Inherited forms of CRC genomics 
 
 
It is estimated that between 3-6% of all CRC cases are associated with highly penetrant 
hereditary GI cancer syndromes and another 25-30% of individuals with CRC report having 
one or more relatives diagnosed with CRC [24]. The two most frequent appeared forms of 
hereditary colorectal cancers are hereditary non-polyposis colon cancer (Lynch syndrome, 
estimated allele frequency 1:350 to 1:1,700) and familial adenomatous polyposis coli 
(estimated allele frequency 1:10,000) [25]. Lynch syndrome results from germ line mutations 
in a class of genes involved in DNA mismatch repair, including MSH2, MLH, MSH6, and 
PMS2 [26]. The second most common hereditary CRC syndrome is familial adenomatous 
polyposis (FAP). However, only a small fraction of all CRCs are associated to FAP caused 
by germ line mutations in APC gene, which encodes a tumor-suppressor protein that is part 
of the WNT signaling pathway [27]. 
 
 
1.4 EXAMPLE of CRC RELATED TARGET 	  
 
The insulin-like growth factor-1 receptor (IGF1R) is a transmembrane receptor tyrosine 
kinase (RTK) that transduces IGF1 and IGF2 signals which play an important role in growth, 
differentiation and survival of cells [28]. Two extracellular α-subunits form disulphide-bonds 
to two transmembrane-spanning β-subunits with cytoplasmic tyrosine kinase activity. 
Binding of IGF1 or IGF2 to the ectodomain of IGF1R induces a structural rearrangement 
resulting in phosphorylation of specific tyrosine residues in the cytoplasmic domains, 
stimulating catalytic (tyrosine kinase) activity and generating recruitment sites of Insulin 
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Receptor substrate proteins and adapter protein Src homology 2 domain containing (Shc), 
among other signaling proteins. Phosphorylation of these substrates by IGF1R leads to 
activation of mitogen-activated protein kinase (MAPK) and phosphoinositide 3’-kinase 
(PI3K) signaling cascades [29]. The over expression of the IGF1R has been implicated in 
different types of tumor systems including CRC [30]. A correlation between the IGF1/2 
expression levels and tumor progression has been consistently documented and extensively 
studied with various approaches to down-regulate the IGF1R pathway. These target 
approaches include a reduction of ligand levels of bioactivity and an inhibition of receptor 
function using receptor-specific antibodies or small-molecule tyrosine kinase inhibitors [31] 
(Figure 2). 
 
 
Figure 2. IGF1R targeted strategies. (A) The binding of insulin to its receptor triggers a 
diversity of downstream pathways (Green arrow:  inducing downstream pathways). (B) Anti-
ligand approaches including lower ligand concentration or the use of ligand-specific 
antibodies. (C) Anti-receptor approach suggests that most receptor-specific antibodies 
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effectively block the IGF1R as well as IGF1R hybrids but don’t act on insulin receptors. (D) 
Receptor inhibitor such as tyrosine kinase inhibitors (Red arrow: inhibiting downstream 
pathways).  	  
Recently, many small molecule inhibitors and antibodies specifically target the IGF1R 
are in preclinical and early clinical development such as CP-751, 871 from Pfizer clinical 
trial phase I-III [32]. It is estimated that at least 10 different drug candidates are being 
evaluated in clinical trials and early results have justified expansion of clinical trial programs 
[31] These small molecules inhibitors have high selectivity and orally active. A recent study 
summarized that IGF-1R inhibitor PQIP disrupted abnormal IGF1R signaling in GEO human 
colon cancer cells resulting in the induction of cell death. Studies with orthotopic colon 
carcinoma animal models in vivo suggested antitumor activity without significant weight loss 
and toxicity [33]. Therefore, based on various therapeutic strategies that target IGF1R has 
demonstrated impressive antineoplastic activity in laboratory models and clinical trials, 
IGF1R has the potential to serve as a target for colorectal cancer therapy. 
 
 
1.5 ANTICANCER DRUG REPURPOSE 
 
 
 
Drug development requires an average of 13 years of research and an investment of 
US$1.8 billion to bring a single drug from the bench to a patient’s bedside [34]. Researchers 
and clinicians have adopted numerous strategies to reduce the cost of the drug discovery. One 
of the strategies is to find potential new use in established non-cancer drugs already approved 
and demonstrate an acceptable level of safety and tolerability. “Drug repurposing” or 
“repositioning” refers to the use of an old drug for a new indication. The major advantage of 
this approach is that their pharmacokinetic pharmacodynamics and toxicity profiles are 
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generally well known.  
There are some strategies to effectively identify and implement current non-cancer 
drugs for cancer-related treatment [35]. The first idea is that almost all drugs used in human 
therapy will produce off-target side effects in addition to their original indications. The 
second idea is based on the finding that many different diseases share common molecular 
pathways and targets in the cell. Therefore, it is highly possible that the same drug could be 
therapeutic for more than one disease. Here are some examples of non-cancer drugs are 
successfully repurposed as anti-cancer drugs for colorectal cancer (Table 2) 
 
 Table 2. Summary of non-cancer drugs repurposed as anti-CRC drug 	  
Drug Original indication New anticancer indications Reference 
Aspirin Analgesic, antipyretic  CRC [1] 
Celecoxib Osteoarthritis, 
rheumatoid arthritis 
CRC, lung cancer [2] 
Metformin Diabetes mellitus  Breast, adenocarcinoma, 
prostate cancer, CRC 
[3] 
Rapamycin Immunosuppressant  CRC, lymphoma, leukemia  [4] 
Noscapine Antitussive, 
antimalarial, analgesic  
Multiple cancer types  [5] 
Troglitazone Diabetes mellitus Metastatic colorectal cancer [6] 
Enilconazole Antifungal Metastatic colorectal cancer [7] 
Citalopram Depression Metastatic colorectal cancer [7] 
Mebendazole Helmintic Colon cancer [8] 
 	  
 
In recent years, the number of drug-repositioning methods has increased greatly. It is of 
great importance to better understand existing methods and prioritize them based on specific 
studies. Transcriptomic approaches can relate a drug to an expression-based phenotype. For 
example, the CMap approach was one of the first attempts to take a more holistic view of 
these transcriptomic data and apply them to link expression profiles across conditions [36]. 
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Genetically, genome-wide association studies (GWAS) have shown the association between 
genetic variants and polygenic diseases, resulting in the identification of genes proximal to 
these variants being linked to numerous complex diseases. There are some challenges by 
using GWAS data [37]. Pathway- or network-based drug-repurposing methods utilize disease 
omics data, available signaling or metabolic pathways, which are still the key ways for the 
repositioned drugs [38]. From a methodological point of view, the computational drug-
repurposing methods can be classified into target-based, knowledge-based, signature-based, 
pathway-based, and targeted-mechanism-based methods. The following figure shows a 
summary of the repurposing methods (Figure 3). 
 
Figure 3. Summary of existing drug-repurposing methods. The computational drug-
repurposing methods can be classified into target-based, knowledge-based, signature-based 
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pathway-based, and targeted-mechanism-based methods. Different disciplines are also 
integrated to do the drug repurposing research such as Cheminformatics, Bioinformatics, 
System or Network biology. 
 
1.6 POLYPHARMACOLOGY AND DRUG DISCOVERY 	  
 
Recently, designing a single molecule able to simultaneously and specifically interact 
with multiple targets is gaining more interests in drug discovery, which is referred as 
“polypharmacology” differed from combination therapy [39, 40]. Current research focuses on 
two aspects of polypharmacology: (1) unintended polypharmacology can lead to adverse 
effects; and (2) polypharmacology across several disease-relevant targets can enhance 
therapeutic efficacy, prevent drug resistance, or reduce therapeutic-target-related adverse 
effects [41]. Interestingly, it is by now generally recognized that several approved drugs elicit 
their therapeutic effect through complex polypharmacology [42]. Figure 4 is well illustrated 
the concept of polypharmacology, which is already published by our lab in 2014 [43].  
 
Figure 4. The Polypharmacology wide target networks. (A) The predicted targets of six 
known abused/approved drugs (opioids: codeine and DB01532; benzodiazepines: 
bromazepam and alprazolam; barbiturates: secobarbital and pentobarbital). (B) The predicted 
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targets of 3 approved drugs for Drug Abuse treatments (methadone, naltrexone, and 
buprenorphine). This figure was from our lab previously published paper [43]. 	  	  
Polypharmacology is largely relevant for diseases associated with wide target networks 
and cellular pathways such as neurodegenerative diseases and different types of cancer with 
complicated cellular pathways. The excessive proliferation and survival of cancer cells can be 
sustained by deregulation in the expression or activity of different proteins. Tumors secrete 
vascular endothelial growth factor (VEGF) and platelet-derived growth factors triggering 
angiogenesis to form endothelial cells and pericytes. Also, activated fibroblasts also secrete 
enzymes, which degrade the extracellular matrix and make room for the tumor growth. Today, 
many effective kinase targeted therapies for cancer treatment can hit on the multiple sensitive 
target nodes, which illustrate the observed efficacy of marketed kinase inhibitors in the 
treatment of several forms of cancer. Simultaneous inhibition of multiple kinases is now 
considered as a promising therapeutic strategy. In addition, polypharmacological anticancer 
drugs are also believed to prevent anti-cancer drug resistance [44]. 
The major challenge of polypharmacology is the ability to rationally design multi-target 
ligands. In addition, further methodological advancements are of great importance. To meet 
this demand, dedicated efforts are made by integrated approaches involving medicinal 
chemistry, genetics, chemical biology, and computational chemistry [45]. 
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2.0 MATERIALS AND METHODS 	  
 
2.1 COLORECTAL CANCER DOMAIN SPECIFIC KNOWLEDGEBASE (CRC-KB) 	  
 
To meet the demands of CRC drug development, an integrated cloud 
computing server, CRCPlatform, has been constructed with a large collection of 
CRC relevant chemogenomics data, including genes, protein targets, and 
chemical molecules with their bioactivity records, bioassays and references as 
well as CRC drugs of FDA approved or in clinical trial. CRC Platform 
(http://cbligand.org/CRC) also provides powerful computational tools such as 
our established TargetHunter and HTDocking for new targets identification, drug 
repurposing, polypharmacology analysis associated with CRC. On the other hand, 
our group has already developed several disease domain specific knowledgebase, 
including a drug abuse knowledgebase (DA-KB) [43], an Alzheimer’s disease 
knowledgebase (AlzPlatform: http://www.cbligand.org/AD) [46]. To summarize, 
it is of great significance to build the CRCPlatform for investigating CRC targets, 
small chemical molecules, which will facilitate the understanding the mechanism 
of polypharmacology and anti-CRC drug discovery. 
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2.2 DATABASE INSFRASTRUCTURE AND WEB INTERFACE 	  
   
CRCPlatform was rooted from our established web-interface molecular database 
prototype CBID (www.CBLIgand.org/CBID) [47]. It is constructed with a MySQL 
(http://www.mysql.com) database and an apache (http://www.apache.org/) web server, and 
implemented with our developed chemogenomics tools.  
 
2.2.1 Web-interface 	  
 
An accessible and easy-to-use web interface was offered with effective and efficient 
search engine for the detailed data on CRC, written in PHP language (http://www.php.net/). 
CRCPlatform provides two types of structure query function for retrieval of bioactivity 
information: substructure and similarity. Open Babel [48] is utilized as the structural 
searching engine and JME [49] supplies the input interface for search. Users can either draw 
a chemical structure, or upload and submit a file containing the structure of a small molecule 
in the format of SMILES, sdf, mol, or cdx. After submission, the search will be performed 
automatically at the server side with GPU accelerating computing approach, and the results 
can be retrieved and shown to the user side on a new page, containing structure of compound, 
target name, and the corresponding reference link. 
 
2.2.2 Data collection and contents 
	  
 
We have data-mined CRC-related genes, proteins, pathways, compounds with 
bioassays from public databases and literatures, and have integrated them into our 
CRCPlatform. The current version of CRCPlatform is comprised of the following features 
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and we will keep updating our information for CRC, and involve additional sections of data 
in the future. 
CRC genes/proteins. We collected proteins as potential targets for CRC based on the 
target information of CRC drugs that are FDA-approved or currently in the clinical trials. 
These targets information were collected from literature, patents, and some public databases, 
such as DrugBank [50] (www.drugbank.ca/), ClinicalTrials.gov (clinicaltrials.gov/), 
PubChem [51] (pubchem.ncbi.nlm.nih.gov/), PubMed (www.ncbi.nlm.nih.gov/pubmed), 
Cancer.gov [52] (www.cancer.gov/) and NCI (National Cancer Institute). These CRC related 
target genes and proteins were then mapped to UniportKB proteins and genes.  
CRC related Pathways. The CRC related pathways were achieved via the publicly 
available database KEGG [53, 54] (http://www.genome.jp/kegg/).  
Chemicals of CRC target proteins. Besides CRC drugs of FDA approved or in 
clinical trials, chemicals that directly interact with the CRC targets were also archived in our 
database. The compounds were from journal articles and archived in CHEMBL [55] 
(www.ebi.ac.uk/chembl/). The corresponding bioassays to validate the interactions between 
these molecules and the target proteins were also collected.  
 
 
2.3 POLYPHARMCOLOGY ANALYSIS TOOLS 	  
 
 At present, one of the challenges is how to identify bonafide and viable targets and 
efficiently exploit these for the development of selective nontoxic cancer therapies, to 
overcome the major drawbacks of conventional cytotoxic cancer chemotherapy [56]. On the 
other hand, small molecules with desired properties are considered as top priorities for CRC 
drug design. The CRCPlatform provides chemogenomics and cheminformatics data to 
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explore the potential CRC targets or off-targets, ADME (absorption, distribution, metabolism, 
excretion), and toxicity prediction (http://www.cbligand.org/Tox), as well as molecular 
properties, the properties explorer (http://www.cbligand.org/OP/Property_Explorer.php) and 
drug-likeness calculations. The chemogenomics tools based on state-of-the-art machine 
learning algorithms developed by our group have been implemented on the CRCPlatform to 
assist CRC drug design and target identification as showed below.  
2.3.1 HTDocking 
We constructed online high-throughput docking program (HTDocking, 
http://www.cbligand.org/CRC/docking_search.php) in our CRCPlatform. HTDocking online 
program aims to explore multiple druggable protein targets and small molecule interactions 
and their potential pharmacology. In our HTDocking for CRC, files for the structures of CRC 
target proteins were downloaded from Protein Data Bank. AutoDock Vina is utilized in 
HTDocking program, which offers a multi-facet capability, high performance rate and 
enhanced accuracy to facilitate effortless usage [57]. It can provide 3-5 predicted binding 
affinity values (ΔG values) from different poses for each compound in a binding pocket of a 
protein [46]. The best binding affinity value is considered as docking score. The calculation 
of docking score is pKi=-log (predicted Ki) where the predicted Ki=exp(ΔG*1000/(1.987191*298.15)) . 
According to the docking score of a queried compound from each protein structure, we can 
rank the potential CRC targets. A higher docking score means a good binding affinity 
indicating that the protein could be a candidate target for a small molecule. 
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2.3.2 TargetHunter 
A web-interfaced target identification program, TargetHunter (http://cbligand.org/
TargetHunter), was built in CRCPlatform to predict the biotargets or off-targets of 
compounds [58]. TargetHunter predicts target for small molecules by powerful data-mining 
algorithm (TAMOSIC), which is based on the principle that compounds with structural 
similarities have similar physicochemical properties and potentially similar biological 
profiles. What’s more, Tanimoto threshold as an important parameter of TAMOSIC can 
exclude irrelevant targets [59]. There are five prominent features of TargetHunter: (a) User-
friendly interface; (b) History data retrieval; (c) Multiple options of specific databases and 
fingerprints; (d) High accuracy; (e) Bioassay finder or Bioassay GeoMap function to easily 
find the potential collaborators who may already have the bioassays established for predicted 
targets validation. 
2.4 EXPERIMENT 
2.4.1 Cell culture and treatment 
Human colorectal cancer cell line HCT116 was obtained from American Type Culture 
Collection (Manassas, VA, USA).  Cells were cultured in McCoy’s 5A modified medium 
(Invitrogen, Carlsbad, CA, USA) supplemented with 10% defined fetal bovine serum (Hyclone, 
Logan, UT, USA), 100 units/mL penicillin, and 100µg/mL streptomycin (Invitrogen). Cells 
were maintained in a 37 °C incubator at 5% CO2. 
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Cells were plated in 12-well plates at 20% to 30% density 24 hours before treatment.  
The DMSO (cat# D2650, Sigma, St Louis, MO, USA) stocks of compounds were diluted to 
appropriate concentrations with the cell culture medium before adding to cells. 
 
2.4.2 Cell growth and analysis of apoptosis 	  	  
Following treatment, floating and adhering cells were collected at 72 hr. For analysis of 
apoptosis by nuclear staining, cells were resuspended and fixed in PBS solution containing 
3.7% formaldehyde, 0.5% Nonidet P-40 and 10 µg/ml Hoechst 33258 (Molecular Probes). 
Apoptosis was assessed through microscopic visualization of condensed chromatin and micro 
nucleation as previously described [60]. A minimum of 300 cells was analyzed in triplicate.  
One thousand HCT 116 cells/well were plated in 96-well plates 24 hours prior to 
treatment and treated for 72 hours.  Cell proliferation in triplicates was measured using Cell-
Titer 96 Aqueous One Solution Cell Proliferation Assay (G3581, Promega) according to 
manufacturer’s recommendations.  A490 nm was measured with a Victor III (Perkin-
Elmer/Wallace) plate reader.  Each experiment was done in triplicate and repeated at least 
twice.  The values were normalized to that of the vehicle control and displayed with the 
means with one standard deviation (SD) [61].  
 
2.4.3 Antibodies and western blotting 	  
 
Cells were harvested in 2× Laemmli buffer (0.125M Tris-HCl at pH 6.8, 10% β-
mercaptoethanol, 4% sodium dodecyl sulphate, 20% glycerol, 0.05% bromophenol blue) and 
then centrifuged at 13,000 RPM for 10 minutes.  Proteins were resolved on 10% NuPAGE gels 
(Invitrogen).  Gel electrophoeresis was carried out for 1 hour at 160v in MES buffer 
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(Invitrogen).  Protein was then transferred to PVDF membranes using a TransBlot SD semi-dry 
transfer cell (Biorad, Hercules, CA).  Membranes were blocked for nonspecific binding with 5% 
nonfat milk in TBS-T for one hour at room temperature and then incubated in primary antibody 
overnight at 4ºC. Primary antibodies cleaved caspase-3 (#9661) and cleaved caspase-9 (#9501) 
(Cell Signaling, Beverly, MA) were used at a 1:1000. Following primary antibody 
hybridization, membranes were washed with TBS-T and incubated in appropriate HRP-
conjugated secondary for 1 hour at room temperature. Goat-anti-rabbit (31462) (Pierce, 
Rockford, IL) was used as the secondary antibodies.  Presence of antibody binding was 
detected using Western Lighting - Plus ECL (Perkin Elmer, Waltham, MA) according to 
manufactures specifications.  Membranes were then exposed on blue X-ray film (Phenix 
Research Products, Candler, NC) [62]. 
 	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  	  
20	  
3.0 RESULTS 
3.1 COLORECTAL CANCER RELATED TARGETS, PATHWAYS, AND DRUGS 
CRCPlatform (www.cbligand.org/CRC) contains 1059 CRC related proteins, 
corresponding with 15 FDA-approved and 396 agents in clinical trials for CRC treatment, 
271 CRC related pathways and CRC targets related bioassay studies. Figure 5 shows the 
detailed information of CRCPlatform. 
Figure 5. The homepage of CRCPlatform. 
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The majority of CRC target proteins are enzymes, such as cyclin-dependent kinase 
2 (CDK2), Serine/threonine-protein kinase B-Raf (BRAF), CYP450 and Catechol O-
methyltransferase (COMT) etc. Additionally, membrane receptors, such as Beta-2 
adrenergic receptor (ADBR2), Endothelin-1 receptor (EDNRA), Ephrin type-A receptor 2 
(EPHA2); ionic channels, such as Potassium voltage-gated channel subfamily D member 2 
(KCND2), transporters like ATP-binding cassette sub-family G member 2 (ABCG2) are 
also included in the 1051 target proteins. In addition to 15 approved and 396 clinical trial 
CRC agents and their corresponding target genes and proteins, CRCPlatform also contains 
some target proteins from drugs for other types of cancers, which might have the potential 
to be repurposed for treatment of colorectal cancer (Figure 5). 
Figure 6. The classification of CRC targets and anti-CRC drugs collected in 
CRCPlatform. The CRC related targets were classified into enzyme, membrane receptor, 
transcription factor, transporter, ion channel, and surface antigen etc. The majority of these 
targets belong to enzymes (accounting for 52%). We mainly focused on the anti-CRC drugs 
approved by FDA and those in different phases of clinical trials. 
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By statistical analysis of the CRC drugs, the different development phases for top list 
20 drugs were plotted referring to their corresponding targets. As shown in Figure 6, the 
DNA is the major target for CRC drugs on the market, four approved interact directly with 
DNA molecule to achieve their therapeutic effect, such as Fluorouracil, Capecitabine, 
Oxaliplatin, and Carboplatin. Other approved CRC drugs act on several other targets 
incorporated into angiogenesis, signaling and DNA synthesis, including Cetuximab and 
Panitumumab target EGFR, Aflibercept and Bevacizumab hit VEGF-A, Irinotecan 
Hydrochloride interacts with TOP1, Leucovorin is related with thymidylate synthase (TYMS), 
and Regorafenib acts on multiple tyrosine kinases like VEGFR2, BRAF, AKT and ABL.  
 
These traditional targets for cancer chemotherapy relevant with DNA replication (DNA, 
TYMS, and TOP1 [63]) and angiogenesis (VEGF, VEGFR, EGFR, ERBB2) not only 
account for the major part of market drugs, but also pose the potential to develop new drugs 
for CRC, based on the large number of Phase 1, Phase 1|Phase 2, and Phase 2 drugs, and 
several Phase 3 drugs. Compare the ratio of different clinical phases for each targets, some 
targets like VEGFR (phase 1+phase1|2:phase 2: phase 3=8:3:1) have more potential in the 
future than some others like EGFR (phase 1+phase1|2:phase 2: phase 3=6:6:0) [64]. 
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Figure 7. Statistical analysis of CRC drugs and their targets in different 
developing clinical trial phases.  
Moreover, some relative new targets has raised more attention recently, such as the 
tyrosine kinases BRAF, KIT, ABL, and AKT [65], enzyme regulate inflammation COX-2 
[66] and interleukins, with larger percentage of drugs in phase 1 and phase 1|2 comparing 
with traditional targets, sometimes with a good ratio and even some drugs in phase 4 (already 
in the market) like COX-2 (phase 1+phase1|2:phase 2: phase 3:phase 4=5:2:2:2).  
Furthermore, some targets have drug that has been terminated in early stage of clinical trials, 
indicating that acting on these targets may have undesired toxicity effects, for example, DNA 
and TOP 1 [63] both have withdrawn drugs, which means involved in the DNA replication 
process can kill tumor cells but sometimes poisonous to normal cells.  
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Interestingly, we also find many agents still in clinical trial for CRC, which have 
already been in the market for a long time to treat other diseases, especially for other cancers. 
For instance, Pertuzumab [67] (targeting ERBB2), still in Phase 1 for CRC, is an approved 
drug for metastatic breast cancer. Vandetanib [68], used in clinic for nonresectable, locally 
advanced, or metastatic medullary thyroid cancer; Sorafenib Tosylate [69], approved for 
primary kidney and liver cancer; Gemcitabine [70], indicated for the treatment of advanced 
ovarian cancer, metastatic ovarian cancer; locally advanced, or metastatic non-small cell lung 
cancer and adenocarcinoma of the pancreas; Lenalidomide, approved for multiple myeloma; 
Carmustine, treatment for several types of brain cancer, are also in clinical trial for CRC 
therapy. Actually, nearly half of trials drugs in Phase 1 and Phase 2 are approved for other 
diseases, infection, inflammation and other types of cancer, indicating it is a good strategy to 
study the existing drugs in the chemotherapy for other cancer in order to find a new drug for 
CRC. 
 
The statistic of CRC targets was also plotted according to the pathways the targets 
involved.  Figure 7 shows the top list pathways with more than 20 CRC related targets 
involved.  Not surprisingly, we found the pathway of cancer (hsa05200) is the number one 
pathway with 111 related targets. Also, many pathways involved in carcinogenesis are on the 
top list pathways, such as PI3K-AKT signaling pathway (hsa04151), MicroRNAs in cancer 
(hsa05206), MAPK signaling pathway (hsa04010), Ras signaling pathway (hsa04014), Focal 
adhesion (hsa04510), Rap1 signaling pathway (hsa04015), Viral carcinogenesis (hsa05203), 
TNF signaling pathway (hsa04668), ErbB signaling pathway (hsa04012), Chemokine 
signaling pathway (hsa04062), Transcriptional misregulation in cancer (hsa05202), Cell 
Cycle (hsa04110), Apoptosis (hsa04210), JAK-STAT signaling pathway (hsa04630). 
Moreover, metabolic pathway (hsa01100) is ranking the second pathway, and many pathways 
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related to metabolism are also on the top list. Furthermore, there are many pathways relevant 
to different kinds of infection on the top list, for example, HTLV-I infection (hsa04014), 
Epstein-Barr virus infection (hsa05169), Viral carcinogenesis (hsa05203), pathogenic 
Escherichia coli infection (hsa05130), T cell receptor signaling pathway (hsa04660), 
revealing a close relationship between the carcinogenesis and viral infection. Additionally, 
pathways for other cancer are easily to be found in the top list pathways, some even involved 
more targets than colorectal cancer pathway (maybe caused by the smaller total number of 
targets), such as Prostate cancer (hsa05215) and Small cell lung cancer (hsa05222). It implies 
the similarity among different cancer pathways, providing foundation for the strategy of drug 
repurposing to seek for new drugs for a specific cancer among the existing drug pools from 
the other types of cancer. 
Figure 8. The top list pathways with more than 20 CRC related targets involved. 
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Table 3.  Detailed information of KEGGID and pathway names 
 
KEGGID Pathway Name  
hsa05200 Pathways in cancer - Homo sapiens (human) 
hsa01100 Metabolic pathways - Homo sapiens (human) 
hsa04151 PI3K-Akt signaling pathway - Homo sapiens (human) 
hsa05206 MicroRNAs in cancer - Homo sapiens (human) 
hsa04010 MAPK signaling pathway - Homo sapiens (human) 
hsa05166 HTLV-I infection - Homo sapiens (human) 
hsa05205 Proteoglycans in cancer - Homo sapiens (human) 
hsa04014 Ras signaling pathway - Homo sapiens (human) 
hsa04510 Focal adhesion - Homo sapiens (human)  
hsa05169 Epstein-Barr virus infection - Homo sapiens (human)  
hsa04015 Rap1 signaling pathway - Homo sapiens (human)  
hsa05203 Viral carcinogenesis - Homo sapiens (human)  
hsa05215 Prostate cancer - Homo sapiens (human)  
hsa04060 Cytokine-cytokine receptor interaction - Homo sapiens (human)  
hsa05161 Hepatitis B - Homo sapiens (human)  
hsa05130 Pathogenic Escherichia coli infection - Homo sapiens (human)  
hsa04066 HIF-1 signaling pathway - Homo sapiens (human)  
hsa05164 Influenza A - Homo sapiens (human)  
hsa04660 T cell receptor signaling pathway - Homo sapiens (human)  
hsa04668 TNF signaling pathway - Homo sapiens (human)  
hsa04012 ErbB signaling pathway - Homo sapiens (human)  
 	  
3.2 NATURAL PRODUCTS FOR COLORECTAL CANCER 	  	  	  
Natural products (NPs) are evolutionarily designed and contain more complex and 
challenging structures than synthetic compounds [71]. NPs play a significant role 
in cancer therapeutics, and recently more attentions have been paid to the drug discovery of 
major lethal malignancies, such as CRC. Many natural products and their analogues have 
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been identified as potent anti-cancer agents such as Taxol, Vincristin, Campothecin, and 
more various plants are being identified[72]. We collected natural compounds from the 
literature with reported anti-CRC activities (Table 4). Curvularin, aloe emodin, and 
kaempferol were selected from Table 4 to further study their potential anti-CRC mechanisms 
at molecular level via identification of their new targets. 
Table 4. Compounds from natural products with anti-CRC activities 
Name Chemical 
Structure 
Molecula
r 
Weight 
Clog
P 
Plant Source 
 6-gingerol 294.39 2.94 Zingiber officinale Roscoe 
 Apigenin 270.24 2.91 Slaginella 
tamariscina(Beauv.)Spring 
 Baicalin 446.36 0.77 Scutellaria baicalensis 
Georgi 
 Berberine 322.34 -0.71 Coptis chinensis Franch. 
 Bergenin 328.27 -1.50 Bergenia purpurascens 
(Hook. f. et Thoms.) Engl. 
 Camptothecin 348.36 0.90 Camptotheca Acuminata 
 Capsaicin 305.42 3.75 Capsicum annuum 
 Cardamonin 270.28 3.49 Alpinia katsumadai Hayata 
O
HO
O
OH
O
OHO
OH
OH
O
OO
O
OHO
HO
HO
OH
HO
OH
HO
N+
O
O
O
O
OH O
OH
OH
OH
O
O
HO
O
O
O
N
N
HO
O
H
N
OH
O
O
OOH
HO
28	  
 Cinobufagin 442.55 3.30 Bufo bufo gargarizans 
Cantor 
 Curcumin 
368.39 2.25 Curcuma longa L. 
 Dihydroartemisi-
nin   
284.35 2.45 Artemisia annua L. 
 Diosgenin 414.63 5.91 Dioscorea opposita Thunb. 
 Epicatechin 
gallate  
442.38 2.16 Camellia 
sinensis(L.)O.Kuntze［The
a sinensis L.］ 
 Epigallocatechin 
gallate  
458.38 2.07 Camellia 
sinensis(L.)O.Kuntze［The
a sinensis L.］ 
 Evodiamine 303.37 3.66 Evodia 
rutaecarpa（Juss.）Benth. 
 Gambogic acid 628.76 8.11 Garcinia hanburyi Hook.f. 
 Honokiol 266.34 4.50 Magnolia officinalis 
Rehd.et Wils. 
 Matrine 248.37 1.5 Sophora flavescens Ait. 
 Oridonin 364.44 -0.13 Rabdosia rubescens 
（Hamst.） C. Y. Wu et 
Hsuan 
 Piperidine 85.15 0.94 Piper longum L. 
 Resveratrol 228.25 2.83 Veratrum nigrum L. 
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 Ursolic acid 456.71 8.63 Hedyotis diffusa 
Willd.[Oldenlandia diffusa 
（Willd.） Roxb.] 
Aloe emodin 270.24 2.70 Aloe barbadensis Miller 
Andrographo-lide 350.46 2.12 Andrographis paniculata 
（Burm. f. ） Nees 
Baicalein 270.24 3.00 Scutellaria baicalensis 
Georgi 
Boswellic acid 456.71 9.33 Boswellia carterii Birdw. 
Caffeic acid 
phenethyl ester 
284.31 3.30 Apis cerana Fabr 
Cantharidin  196.20 0.18 Mylabris phalerata Pallas 
Casticin 374.35 2.10 Vitex trifolia L. var. 
simplicifolia Cham. 
Coumarin 217.27 2.32 Psoralea corylifolia L. 
Emodin 270.24 3.62 Rheum palmatum L 
Ferulic acid 194.19 1.42 Angelica sinensis （Oliv.） 
Diels 
Genistein 270.24 1.74 Kummerowia striata 
（Thunb.）Schneidl. 
Ginsenoside Rg3 785.03 6.29 Panax ginseng C. A. Mey. 
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Protopanaxadiol 460.74 6.78 Panax ginseng C. A. Mey. 
Ginsenoside Rh2 622.88 6.93 Panax ginseng C. A. Mey. 
Indirubin-3’-
monoxime 
279.30 1.18 Isatis indigotica Fort. 
Kaempferol  286.24 2.10 Kaempferia galanga L. 
Luteolin 286.24 2.31 Reseda odorata 
Oxymatrine 264.37 1.63 Sophora flavescens Ait. 
Pinosylvin  212.25 3.50 Dioscorea opposita Thunb. 
Plumbagin 188.18 2.78 Plumbago zeylanica L 
Puerarin 416.38 0.02 Pueraria lobata 
（Willd.）Ohwi 
Rocaglamide 505.57 3.73 Melia toosendan Sieb. et 
Zucc. 
Shikonin 288.30 3.04 Arnebia euchroma (Royle) 
Johnst. 
Silibinin 482.44 1.95 Silybum marianum (L.) 
Gaertn.[Carduus marianus 
L.] 
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Tanshinone IIA 294.35 5.74 Slauia miltiorrhiza Bunge 
Thymoquinone  164.20 2.17 Mosla grosseserrata 
Maxim.[Orthodon 
groswsweserratum 
(Maxim.)Kudo] 
Triptolide 360.41 -0.46 Tripterygium wilfordii 
Hook. f. 
Wogonin 284.27 3.33 Scutellaria baicalensis 
Georgi 
Zerumbone 218.34 5.28 Camellia 
sinensis(L.)O.Kuntze [Thea 
sinensis L.] 
Quercetin 302.24 1.50 Sophora japonica L. 
Allicin 162.27 1.9 Allium sativum L. 
Curvularin 292.33 2.38 Patrinia scabiosaefolia 
Fisch. ex Link. 
3.2.1 New targets identification for curvularin 
 According to the report, one research group isolated the (S)-curvularin, kaempferol, 
and some other constituents from the Traditional Chinese Herbal, the root of Patrinia Scabra, 
which is originally used for the gastrointestinal tract diseases in Chinese Medicine [73]. In 
addition, (S)-curvularin is a kind of fungal metabolites produced by a number of fungi such 
as Curvularia, Penicillium for which antibacterial, cytotoxic, nemeticidial, antitrypanosomal 
and NF-κB inhibiting activities have been reported [74]. Some researchers also showed that 
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(S)-curvularin may reduce the expression of the proinflammatory enzyme iNOS in a 
glucocorticoid-resistant model of rheumatoid arthritis by inhibiting the JAK/STAT signaling 
pathway [75, 76]. We mainly focused on elucidating the potential mechanism of curvularin 
by finding new CRC-related targets with the help of our established tool TargetHunter 
(Figure 8).  
Figure 9. Overview of targets predictions for curvularin by TargetHunter. 
In order to validate these predicted targets for curvularin efficiently, we applied the 
unique and useful function of TargetHunter to find the potential collaborators nearby our area 
by clicking ‘find assay nearby’. 
We further analyzed the nuclear receptor ROR-gamma for curvularin by SYBYL 
docking results comparisons. Figure 9A shows the interactions between ChemBL4802050 
and nuclear receptor ROR-gamma (PDB: 4NIE). Its docking score is 5.4104. The key 
residues for this ligand are Tyr B308, Lys B311, Glu B303, and Asp A291. The major 
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interaction between CHEMBL4802050 and its residues is hydrogen bond. Their distances are 
listed in the table for the comparison. Figure 9B shows the interactions between curvularin 
and nuclear receptor ROR-gamma (PDB: 4NIE). The docking score is 6.9184. The key 
residues for the curvularin are Asp A291, Gly B307, Arg B310, Asp A291, and Tyr B308. 
We compared these two docking results by listing the key residues in. These two compounds 
share the two residues Asp A291 and Tyr B308. Based on the principle that similar chemical 
structures have similar bioactivities, curvularin might act on the target. 
Figure 10. Docking results of CHEMBL4802050 (A) and Curvularin(B). (A) The 
interactions between ChemBL4802050 and nuclear receptor ROR-gamma (PDB: 4NIE). Its 
docking score is 5.41. The key residues for this ligand are Tyr B308, Lys B311, Glu B303, 
and Asp A291. The major interaction between CHEMBL4802050 and its residues is 
hydrogen bond. Their distances are listed in the table for the comparison. (B) The interactions 
between curvularin and nuclear receptor ROR-gamma (PDB: 4NIE). The docking score is 
6.92. The key residues for the curvularin are Asp A291, Gly B307, Arg B310, Asp A291, and 
Tyr B308. 
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3.2.2 New targets identification for aloe emodin  	  
 
Aloe Emodin (AE) is a natural active compound mainly present in the leaves of Aloe 
vera and the rhizome of Rheum palmatum, which are frequently used Traditional Chinese 
Medicinal herbals. AE has been demonstrated to have various pharmacological activities 
including antiviral, antimicrobial and hepatoprotective activities [77, 78]. Also, some studies 
reported that AE exhibited anticancer activity on colon cancer cells, neuroectodermal tumors, 
lung squamous cell carcinoma, and hepatoma cells [79-81].  
 
It is reported the molecular mechanisms involved in the anti-migratory and anti-
angiogenic activity of this hydroxyl anthraquinone in colon cancer cell and AE can down 
regulate MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-κB [82] 
Another research group did the in vitro inhibition experiments indicating that AE caused the 
release of apoptosis-inducing factor and cytochrome c from mitochondria and activated 
caspase-3 leading to DNA fragmentation, nuclear shrinkage and apoptosis, and inhibited 
casein kinase II activity [79]. However, the molecular mechanisms of anti-CRC effect for AE 
are still not completely clarified. The online TargetHunter program is an ideal tool to help 
comprehend the unexplored anticancer targets for understanding anti-CRC mechanism of AE 
at the molecular level. Therefore, the structure of AE was submitted in the form of SDF as a 
query to the online TargetHunter program.  
 
There are two related compounds (CHEMBL53418 and CHEMBL418068) were 
retrieved with similarity scores 0.57 and 0.55 respectively. These two compounds share the 
same target (tyrosyl-DNA phosphodiesterase 1) but the compound CHEMBL418608 with the 
potency of 0.5012µm is more potent than CHEMBL53418. The human tyrosyl-DNA 
phosphodiesterase belong to the phospholipase D (PLD) superfamily. Tdp1 is a monomer 
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composed of two similar domains that are related by a pseudo-2-fold axis of symmetry. Each 
domain contributes conserved histidine, lysine and asparagine residues to develop a single 
active site[83]. Tyrosyl-DNA phosphodiesterase (Tdp1) is a key enzyme involved in the 
repair of Topoisomerase 1 associated DNA breaks by catalyzing the hydrolysis of 3’-
phosphotyrosyl bonds [84]. Colorectal cancer is characterized by the presence of endogenous 
DNA damage [85]. The targeting of DNA repair enzymes for anticancer therapeutic 
intervention can be used as strategy to potentiate the cytotoxicity of currently available DNA 
damaging agents toward cancer cell [86]. Thus, inhibiting Tdp1 might be an underlying anti-
CRC mechanism for AE.  
 
 Additionally, 15-hydroxyprostaglandin dehydrogenase [NAD+] (15-PGDH) targeted 
by compound (CHEMBL418068) is shown to have tumor suppressor activity and to be 
down-regulated in various cancers, including CRC [87]. 15-PDGH controls the rate-limiting 
step in Prostaglandin E2 (PGE2) catabolism by conversion of PGE2 to 15-keto-PGE2 
coupled to the reduction of NAD+ to NADH [88]. PGE2 is the most abundant PG in human 
colon and its overexpression in colorectal neoplasia compared with normal colorectum [89]. 
Recently, a research group suggested that PGE2 levels were significantly higher in the center 
of CRC liver metastasis (CRCLM) compared with peripheral tissue and there were increased 
levels of 15-PGDH protein in the center of CRCLM associated with reduced 15-PGDH 
activity and low NAD+/NADH levels. Furthermore, they concluded that based on the intra-
tumoral differences in PGE2 metabolism is essential for the development of optimal anti-
CRC therapy aimed at the COX-PGE2-15-PGDH [88] (Figure 10). Therefore, 15-PGDH 
might be the potential target of AE for CRC treatment. 
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Figure 11. Crosstalk between Wnt and Prostaglandin signalling. Activation of canonical 
Wnt signalling drives expression of COX2, which catalyzes production of PGE2, and 
repression of 15-PDGH. PGE2 activates the prostaglandin GPCR receptor EP2 releasing the 
Gsα subunit that displaces GSK3 form AXIN, resulting in the stabilization of β-catenin. 
The unique function of Bioassay Geomap integrated in TargetHunter facilitates further 
experimental validation for this prediction. Four research laboratories close to Pittsburgh 
were found by this function (Table 5). Hopefully, they could be the potential partners for the 
further validation of the predicted targets. In a word, our online TargetHunter program 
provides us with an innovative clue to explore new molecular mechanisms for natural 
compounds derived from Traditional Chinese Medicine. 
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Table 5. Potential collaborators found by Bioassay Geomap function of TargetHunter 	  
Target Name Address Reference 
 Tdp 1 Center for Drug Design, Academic Health Center,  
University of Minnesota, Minneapolis, Minnesota 
55455, USA. 
[90] 
 Tdp 1 Department of Medicinal Chemistry and Molecular  
Pharmacology, College of Pharmacy, and the 
Center for Cancer Research, Purdue University, 
West Lafayette, Indiana 47907, USA. 
[91] 
 Tdp 1 Chemical Biology Laboratory, Center for Cancer 
Research, National Cancer Institute, National 
Institutes of Health,  
DHHS, Frederick, MD 21702, USA 
[83] 
 
Bioassay Geomap function shows three research institute could potentially validate our 
predictions not only by TargetHunter but also by our virtual screening compounds. Chemical 
similarity as a criterion for in silico target identification is based on the well-established 
medicinal chemistry concept that structurally similar compounds have similar 
physicochemical properties and possibly similar biological profiles[92, 93]. Leading Tdp1 
inhibitors are categorized into four families according to their structure-activity relationship 
(SAR). Three were amenable for medicinal chemistry follow-up including family 1 members 
are characterized by analogs derived from Paar-Knorr synthesis of pyrroles (Figure 
11,chemical structure in blue box), family 2 members are characterized by a rhodanine 
substructure (Chemical structure in red box seen in Figure 11), and family 3 members are 
characterized by an alkylidene barbiturate moiety (Chemical structure in green box) [94]. 
Based on chemical similarity of reported Tdp1 with a good IC 50 value, we virtual screening 
NCI database to find potentially putative Tdp1 inhibitors. NCI database is publicly available 
from the Enhanced NCI Database Browser: http://cactus.nci.nih.gov/ncidb2.2/(Figure 11).  
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Figure 12. The potential compounds from NCI database are screened for Tdp1 based on 
chemical similarity. 
3.2.3 New target identification for kaempferol 
The capsaicin receptor or transient receptor potential vanilloid type 1 (Trpv1) is a heat-
activated (at 52°C) cation non-selective channel, which is predominantly expressed in the 
distal colon and rectum in the gastrointestinal tract [95]. TRPV1 expression is increased in 
the colon of patients with inflammatory bowel diseases (IBD) known as a risk for the 
development of CRC and this overexpression is thought to contribute to the ongoing pain and 
visceral hypersensitivity in these patients. What’s more, many epidemiologic and 
experimental studies have highlighted the relationship between inflammation and cancer [96]. 
Based on a recent study, the researchers used capsazepine, a TRPV1 antagonist, for its 
ability to sensitize human colon cancer cells to tumor necrosis factor-related apoptosis-
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inducing ligand (TRAIL). They found that capsazepine down regulated cell survival proteins 
(e.g., survivin) and increased the expression of pro apoptotic proteins (e.g., Bax and p53) [97]. 
Furthermore, it is reported that TRPV1 has been used to selectively kill cancer cells by 
activating Ca2+ and Na+ entry, producing a sustained increase in the cytoplasmic 
concentration of these ions, and subsequent cell death by apoptosis and necrosis [98]. 
Immunohistochemical studies have indicated that TRPV1 was expressed in colon 
adenocarcinoma and the concentration of extracellular polyamines known as TRPV1 agonist, 
in tissues of the gastrointestinal tract increase in cancer and inflammation [99, 100]. This 
suggested that TRPV1 may be activated by polyamines in colon cancer, and contribute to the 
cancer pain. Therefore, researchers hold the particular interests in finding potent compounds 
target TRPV1. 
However, so far there are no reported crystal structures of TRPV1. In addition, to our 
knowledge, some of the models of TRPV1 are constructed based on the X-ray structure of the 
voltage-dependent shaker family K+ channel (PDB: 2R9R) [101] from non-TRP family 
channel. Our group constructed the 3D-homology tetramer models of hTRPV1 based on the 
cyro-EM derived structure of rTPV1 and selected the best one by using molecular dynamics 
simulations, energy minimizations, and prescreening. The binding pocket of our model is 
formed by trans-membrane segments S3, S4, the S4-S5 linker and S5 of one monomer, as 
well as segments S5 and S6 of the adjacent monomer (subunit) (Figure 12A) [102]. We used 
this model to explore and compare the detailed interactions between hTRPV1 and its 
antagonist by using molecular docking (Figure 12B).  
 Kaempferol seen in (Table 4) was docked with our lab already established TRPV1 
protein model. Kaempferol, a flavonol widely found in tea and broccoli is claimed to have an 
anti-proliferative effect on colon cancer cell lines [103]. Kaempferol with anti-inflammatory, 
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antiangiogenic properties was previously reported in literature [104]. The docking score of 
Kaempferol and hTRPV1 protein model is 6.62. Their key residues are Tyr 511, Asn551, Thr 
550, Ser 512, Ile 572 [102]. The ligand interacts with residues Tyr 511 and Ile 572 with π-H 
interaction. Asn551, Thr 550 and Ser 512 bound to Kaempferol with hydrogen bond in the 
distance of 1.9 Å, 2.1Å and 2.4Å respectively.  Manual docking partly helps understand how 
Kaempferol works on colon cancer cells at the molecular level. 
Figure 13. Docking analysis of Kaempferol and hTRPV1 protein model. (A) Overview of 
TRPV1 and its binding pocket. The binding pocket of our model is formed by trans-
membrane segments S3, S4, the S4-S5 linker and S5 of one monomer, as well as segments S5 
and S6 of the adjacent monomer (subunit). (B) Docking result of Kaempferol and hTRPV1 
with docking score 6.62. 
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3.3 POLYPHARMACOLOGY ANALYSIS OF ANTI-CRC DRUGS AND THEIR 
TARGETS 
 
 
As a validation procedure, we used our established computational chemogenomics 
method HTDocking to predict the potential targets for several FDA-approved drugs, 
including Lapatinib (a dual tyrosine kinase inhibitor which interrupts the HER2/neu (ERBB2) 
and epidermal growth factor receptor (EGFR) pathways), Axitinib [105] (a multi-targeted 
tyrosine kinase inhibitor), Sorafenib [69] (an inhibitor of several tyrosine protein kinases 
(VEGFR and PDGFR) and Raf kinases), Sunitinib [106] (a multi-targeted receptor tyrosine 
kinase inhibitor), OSI-930 (a novel selective inhibitor of the receptor tyrosine kinases Kit 
(KIT)), and erlotinib [107] (an EGFR receptor inhibitor). The possible interactions between 
these drugs and CRC proteins were predicted and ranked by docking scores. These 
associations were plotted as a polypharmacological interaction network (Figure 13).  
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Figure 14. Polypharmacology analysis of five FDA approved anti-CRC drugs. 
Primarily, we compared our predicted drug-target association against reported ones in 
journal articles and databases such as CHEMBL and WOMBAT. Not surprisingly, among 
our predicted results, the known therapeutic targets or primary targets for these drugs such as 
EGFR, ERBB2, KIT, and Tyrosine-protein kinase ABL1 were ranked on the top of 
corresponding predicted target list, such as (Axitinib, Sunitinib, Erlotinib, Lapatinib, and 
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OSI-930) [108]. Moreover, through comparing the predicted docking scores with the 
experimental Ki or Kd values, we revealed that our predicted binding affinities against these 
targets were consistent with the bioactivity data (Table 6). Furthermore, some additional 
predictions of drug-target associations were also validated through data mining of literatures. 
Our results showed that the predicted interactions between several targets and these drugs 
were also reported in literature, indicating the reliability of the HT docking program for CRC 
(Table 7). In addition, the other predicted associations, though not been reported in literature 
yet, could be indicators of novel targets for these drugs, which needs further experimental 
validations. 
 
Table 6. The comparison of the experimental pKi or pKd data and the predicted pKd 
values for the FDA-approved CRC drugs 
 
Drug Target Docking 
score 
Experimental  
-Log (Kd or 
Ki) 
Reference 
Axitinib Mast/stem cell growth factor 
receptor Kit 
8.93 8.77 [109] 
Axitinib Disintegrin and metalloproteinase 
domain-containing protein 17 
8.12 9.31 [109] 
Axitinib Fibroblast growth factor receptor 
1 
7.15 6.42 [109] 
Axitinib Tyrosine-protein kinase ABL1 6.93 8.82 [109] 
Lapatinib Receptor tyrosine-protein kinase 
erbB-2 
9.46 8.80 AID435402 
Lapatinib Tyrosine-protein kinase ABL1 7.03 6.20 AID435146 
Erlotinib Tyrosine-protein kinase ABL1 6.80 6.40 AID624984 
Erlotinib Receptor tyrosine-protein kinase 
erbB-2 
6.57 7.70 AID435907 
Sorafenib Tyrosine-protein kinase ABL1 7.19 6.80 AID256665 
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Table 7. Verification of other predicted targets of approved CRC drugs by experiment 
 
Approved 
Drug 
Target Docking 
(pKd) 
Actions  
Reference 
Erlotinib Cytochrome P450 1A1 8.59 Substrate [110] 
Erlotinib Cytochrome P450 1A2 8.08 Substrate [111] 
Erlotinib Cytochrome P450 2D6 9.11 Substrate [111] 
Lapatinib Cytochrome P450 
2C19 
9.29 Substrate [111] 
Lapatinib Cytochrome P450 3A4 6.84 Substrate inhibit [112] 
Lapatinib Epidermal growth 
factor receptor 
7.21 Antagonist [113] 
Sunitinib Mast/stem cell growth 
factor receptor Kit 
6.48 Antagonist [114] 
Lapatinib Epidermal growth 
factor receptor 
7.21  [115] 
Erlotinib L-lactate 
dehydrogenase B 
chain 
6.74 Inhibition [116] 
Erlotinib Hemoglobin subunit 
alpha 
6.51 Inhibition 
77.9% 
[117] 
Erlotinib Epidermal growth 
factor receptor 
6.34 Inhibition 
81% 
[118] 
Sunitinib Serine/threonine-
protein kinase Chk2 
7.94 Inhibition [119] 
Sunitinib Ephrin type-A receptor 
2 
7.08 Inhibition [105] 
Sunitinib RAC-alpha 
serine/threonine-
protein kinase 
7.03 Inhibition [119] 
Sunitinib Mast/stem cell growth 
factor receptor Kit 
6.48 Inhibition 
84.8% 
[105] 
 
The predicted drug-target association may also be used to find a novel combined 
medication to achieve improved pharmacological therapeutic effect with reduced side effect 
[108]. Sorafenib is known to inhibit kinases that regulate angiogenesis (VEGFR2), and 
proliferation (BRAF), RET liposomal degradation (RET). For instance, BRAF 
phosphorylates MAP2K1, and thereby contributes to the MAP kinase signal transduction 
pathway, which affects cell division, differentiation, and secretion.  According to our 
prediction, Sorafenib can also interact with tyrosine kinase AKT and ABL1 (Abelson murine 
	   46	  
leukemia viral oncogene homolog 1), which play important roles in the regulation of 
proliferation [69]. On the other hand, Erlotinib is designed to inhibit EGFR tyrosine kinase, 
which is highly expressed in cancer cells. Erlotinib may also bind to other potential targets 
based on our prediction, such as ABL1, CDK2, ERBB2, and several cytochromes P450 [107]. 
CDK2 is required for the transition from G1 to S phase in cell cycle [65]. Combined use of 
Erlotinib and Sorafenib, may further inhibit the angiogenesis by blocking EGFR, VEGFR, 
ERBB2 and ABL1, which are angiogenesis related proteins. Among them, ABL1 regulates 
the CBL (Castitas B-lineage Lymphoma) family of ubiquitin ligases and phosphorylation of 
CBL leads to an increased EGFR stability [120]. ABL1 is also involved in the late stage 
autophagy by regulating lysosomal components; mediates mitochondrial dysfunction and cell 
death by controlling response to oxidative stress, and involved in DNA-damage response and 
apoptosis by translocation with DNA binding site.  
 
Together with other predicted targets, they all play different but important roles in the 
tumor regulation. There are many clinical studies focus on the combination therapy of 
Sorafenib and erlotinib to treat a variety range of cancers, such as non–small cell lung cancer 
(NSCLC) [121], hepatocellular carcinoma [122], advanced pancreatic cancer, and other 
advanced solid tumors [123]. The two drugs provided additional support for studying this 
combination therapy [124] (Figure 13). 
 
Cyclin-dependent kinase 2 (CDK2) is a novel target for erlotinib predicted by 
HTDocking (Figure 13). Based on this new prediction, erlotinib originally was indicated for 
NSCLC [125] and might be repurposed for other type of cancers. We further analyzed the 
interactions between CDK2 and erlotinib by manual docking. First, we aligned erlotinib with 
the original inhibitor indazole [126], and we found that erlotibib matched well with indazole 
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in original co-crystal (Figure 14A) with docking score of 9.89. Then, we analyzed their 
interactions between erlotinib and CDK2. The key residues are Leu 83, Phe 80, Val 64, Ile10, 
Leu 134, Asp145, Ala 31, Ala 144 and Phe 146. The major interactions are hydrogen-bond 
and polar interactions. Erlotinib interacts with Asp 145 through two hydrogen bonds with the 
distance of 2.5 Å and 2.9Å. Erlotinib also binds to Phe146 through polar interactions with the 
distance of 2.1 Å (Figure 14 B and C). 
Figure 15. The detailed information of docking analysis between erlotinib and CDK2. 
(A) The alignment between original CDK2 inhibitor indazole (in white) and erlotinib 
(in blue); (B) The interactions between erlotinib and CDK2; and (C) The detailed information 
for the binding interactions and their key residues. 
3.4 VIRTUAL SCREENING AND EXPERIMENTAL VALIDATION 
 3.4.1 Virtual screening of in-house compounds 
We applied our in-house compound library to the CRCPlatform. Top 10 targets derived from 
FDA approved CRC drugs in CRCPlatform were selected to do virtual screening on our in-
house compound. We found that insulin growth factor 1 receptor (IGF1R) was predicted as 
	   48	  
the potential target for our in-house compounds. IGF1R is frequently expressed in human 
colon cancers and plays important roles in promoting malignancy. The oncogenic effects are 
mainly due to the mitogenic and antiapoptotic properties regulated by their IGF1R [127]. We 
selected those compounds with their docking scores above 6.0 (Table 8). Compound XIE62-
1032, with the highest docking score of 9.58 on IGF1R was further analyzed (Figure 15). 
Key residues of IGF1R, such as Asp 1056, Arg 1128 and Met 1112 interact with XIE62-1032. 
Their major interactions are hydrogen bonds, and the hydrogen-bond distances from Asp1056 
and Arg 1128 to XIE62-1032 are   2.2Å and 2.1 Å, respectively. 
 
Table 8. Top seven in-house compounds with docking score above 6 in complex with 
IGF1R 	  
Compound-ID MW ClogP Predicted Kd (nM) Docking Score 
XIE35-1107 417.48 4.63 6.20 8.21 
XIE95-1170 422.58 6.79 19.96 7.70 
XIE62-1032 391.50 5.11 0.26 9.58 
XIE18-1014 336.38 2.50 106.49 6.97 
XIE18-1025 362.40 1.78 123.08 6.91 
XIE62-1044 306.36 2.73 466.77 6.33 
XIE95-1156 432.67 5.06 268.29 6.57 
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Figure 16. The detailed docking analysis of XIE62-1032 in IGF1R (PDB: 3NW6). 
(A) The overview of compound XIE62-1032 in IGF1R. (B) The docking results of XIE62- 
1032 and IGF1R. 
3.4.2 Experimental validation of in-house compounds 
After the virtual screening and docking analysis, we further validated these top seven 
compounds.  MTS cell proliferation assay and apoptosis analysis were used to test our 
compounds using the HTC116 colorectal cancer cell line.  The MTS assay results showed 
that XIE62-1032 is the most potent compound to inhibit the proliferation of HCT116 cells 
(Figure 16), with an IC50 of 3.77 µM (Figure17).  XIE62-1044 was the second most potent 
compound with an IC50 around 10 µM.  These two compounds were chosen for further 
testing. 
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Figure 17. HCT116 cells were treated with indicated compounds for 72 h.  Cell viability 
was determined by MTS assay.  Results were expressed as means ± S.D. of three 
independent experiments.  
Figure 18. HCT116 cells were treated with XIE62-1032 at different concentrations for 
72 h.  Cell viability was determined by MTS assay.  Results were expressed as means ± S.D. 
of three independent experiments.  IC50 was calculated by Prism. 
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Induction of apoptosis is an important mechanism of many anticancer agents, and 
caspase activation is a hallmark for apoptosis and indicated by cleavage [128] Apoptosis is 
triggered by a series of well-ordered biochemical events and regulated by complex signaling 
networks[129]. Many important pathways controlling apoptosis and cell survival are 
commonly altered in cancer[129]. We observed signs of cell killing such as rounding and 
detachment from plates, and further examined the effects of XIE62-1032 and XIE62-1044 on 
caspase activation.  We observed dose-dependent induction of cleaved caspase-9 and cleaved 
caspase-3 in (Figure 18).  Consistent with the MTS data, cells treated with XIE62-1032 
showed higher levels of cleaved caspase-9 compared to those treated with XIE62-1044.  
Interestingly, XIE62-1032 appeared to strongly induce the expression of caspase-9.  However, 
cleavage of caspase-3 appeared more significant upon XIE62-1044 treatment.  These results 
suggest that our in-house compound XIE62-1032 and XIE62-1044 inhibit colon cancer 
proliferation and promote apoptosis. 
Figure 19.  Cells were treated with XIE62-1032 and XIE62-1044 for 24h at indicated 
concentrations.  The indicated proteins were analyzed by western blotting.  β-actin is a 
loading control. 
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4.0 DISCUSSION 
 
  
 Colorectal carcinogenesis is the complicated adenoma-carcinoma sequence and 
multiple -step tumor genesis that is induced and influenced by multiple molecular pathways, 
gene mutations, and their interactions, which may take decades [130]. In order to reduce the 
impact of CRC, concerted efforts have been made on the prevention, diagnosis, and treatment 
to control colorectal cancer, leading to the accumulation of a large volume of scientific data 
related to CRC. Although PubChem and other databases have archived most of the literatures, 
the published researches are still scattered. So searching, organization, and validation of the 
reported CRC-related small chemical molecules, and exploitation of the previous bioassay 
target research results for CRC are not very easy. 
 
Several CRC-related databases have been reported to associate and analyze the results 
of CRC studies. The CRCgene database provides a comprehensive field synopsis of genetic 
association studies and meta- analyses for all eligible polymorphisms in Colorectal Cancer 
[8]. An integrated Oracle database was also constructed contains information in in CRC 
outcomes, prognosis, and epidemiology, which enables the successful collection of data for 
CRC prognosis cohort studies [131]. Danish database is mainly for clinical studies [132] and 
DUBLIN - Maven Semantic can reach individual research in CRC [133].  However, publicly 
CRC specific chemical genomics (or chemogenomics) database that focuses on small 
molecules targeting CRC-related proteins is still not available as far as we know. 
CRCPlatform bridges the knowledge gap between biology and chemistry related to CRC, 
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improving CRC target studies, drug mechanism explorations, polypharmacology analysis and 
new drug discovery.  
 
Our case studies implied that the protein structure-based HTDocking program has been 
successfully predicted the CRC-related targets for small molecules, such as FDA approved 
drugs, lead compounds and natural products. The reliability of HTDocking program was 
verified by comparison of the predicted values with the reported pKi values for known CRC 
drugs. Furthermore, CRCPlatform offers an alternative way to map the drug –target network 
for the investigation on polypharmacology, clinical combinational therapy and predicting 
potential adverse drug reaction. So far, “one-compound-one-target” therapeutic paradigm has 
been challenged despite the fact that enormous efforts have been made to illustrate the 
pathophysiology, anti-CRC. Recently the multi-target-directed ligand approach has gained 
increasing attention by many research groups, which have developed plenty of novel 
compounds act on various biological targets [134]. For example, we identified CDK2 as a 
new target for erlotinib by polypharmacology analysis, which could be repurposed to treat 
other types of cancer. However, HTDocking is limited to the availability of co-crystal protein 
structures, such as TRPV1 receptor is not included in CRCPlatform.  
 
On the other hand, an online service, the ligand-based TargetHunter, is built on the 
TAMOSIC algorithm to automate the target prediction and it is free accessible to academic 
and industrial researchers [58]. It is of great use for drug repurposing, and the investigation of 
potential side effects (off-target) related to CRC drugs. The new targets identification for the 
compounds of natural products could provide a clue to further investigate the potential 
mechanism of these natural compounds for CRC. What’s more, this powerful cloud-
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computing tool embeds the geographical bioassay locator to facilitate the finding nearby 
collaborators who have published the related bioassay (Table 5).  
 
Based on the experimental validation results of in-house compounds, our CRCPlatform 
acted as a guide to assist finding the proper targets for CRC drug discovery. We virtual 
screened the potential in-house compounds for CRC and found collaborators to validate the 
target prediction of the in-house compounds by using HCT-116 colorectal cancer cell line. 
The MTS assay results suggest that XIE62-1032 is the most potent compound inhibiting the 
cell proliferation, which is consistent with our prediction that XIE62-1032 with the highest 
docking score of 9.58. Additional experimental data indicate that XIE62-1032 treatment 
increases the levels and activation of caspase-9.  
 
The IGF-1R pathway is well known to promote survival and suppress the activation of 
apoptosis mediated by Caspase-9 and caspase-3 [32]. We hypothesized that our in-house 
compound XIE62-1032 might bind to the IGF1R and trigger apoptosis signaling pathway by 
up-regulating capase-9 and capase-3 (see Figure 19). Further experimental validation of the 
binding of our in-house compound XIE62-1032 to IGF1R at protein level are on-going now. 
The potential collaborators are found by Bioassay Geomap implemented in our TargetHunter 
and published literature related to IGF1R. The potential collaborators are listed in Table 9. 
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Table 9. The list of potential collaborators for XIE62-1032 and IGF1R binding assay 
   
Institute name Bioassay Paper 
Department of 
Biochemistry and 
Molecular 
Pharmacology  Skirball 
Institute  NYU school of 
Medicine 
Continuous 
spectrophotometric 
kinase assay 
Small-molecule inhibition and 
activation-loop trans 
phosphorylation of the IGF1 receptor  
Eppley Institute and 
Fred& Pamela Buffett 
Cancer center 
In vitro inhibition 
of IGF1R signaling 
by the selective 
IGF1R kinase 
inhibitor PQIP  
Anti-tumor Activity of IGF-1R 
Kinase Inhibitor PQIP in Colon 
Cancer  
Fox Chase Cancer Center, 
333 Cottman Avenue, 
Room P3165, 
Philadelphia, Pennsylvania  
Kinase selectivity 
profiling,“HotSpot” 
assay platform 
A highly selective dual insulin 
receptor (IR)/insulin-like growth 
factor 1 receptor (IGF-1R) inhibitor 
derived from an ERK inhibitor* 
 
 
 
Table 5. Potential collaborators found by Bioassay Geomap function of TargetHunter 
 
Target Name Address Reference 
Tyrosyl-DNA  
Phosphodiesterase 1  
(Tdp 1) 
Center for Drug Design, Academic Health 
Center,  
University of Minnesota, Minneapolis, 
Minnesota 55455, USA. 
[90] 
Tyrosyl-DNA  
Phosphodiesterase 1  
(Tdp 1) 
Department of Medicinal Chemistry and 
Molecular  
Pharmacology, College of Pharmacy, and 
the Center for Cancer Research, Purdue 
University, West Lafayette, Indiana 47907, 
USA. 
[91] 
Tyrosyl-DNA  
Phosphodiesterase 1 
(Tdp 1) 
Chemical Biology Laboratory, Center for 
Cancer Research, National Cancer Institute, 
National Institutes of Health,  
DHHS, Frederick, MD 21702, USA 
[83] 
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Figure 20. The proposed mechanism of anti-CRC activity of our in-house compound 
XIE62-1032. Our in-house compound binding IGF1R triggers the apoptosis signaling 
pathway. Blue arrows, activation; mangenta arrows, translocation from organelles to 
cytoplasm.  
Our chemogenomics tools make this new approach more convenient and efficient for 
new drug discovery by collecting a variety of CRC related drugs and small molecule with 
identified targets. Also, our CRC Platform provides CRC related pathways, CRC biomarkers 
etc. to assist researchers conducting comprehensive CRC studies.	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5.0 SUMMARY 
CRCPlatform (http://www.cbligand.org/CRC) developed as a publicly accessible 
cloud-computing server provides comprehensive data and efficient tools for CRC drug and 
targets research. We employed our FDA-approved or in different phases of clinical trial drugs, 
natural compounds with anti-CRC activities, and in-house compounds to test and validate our 
CRCPlatform. The results of FDA approved drugs predicted by HTDocking are validated by 
literature via comparison of our HTDocking score and literature reported Ki or Kd value. 
TargetHunter not only can help reveal the mechanisms of natural compounds, but also predict 
the off-target. The GPU for the acceleration of Tanimoto calculation is imbedded in 
TargetHunter accelerating the chemical similarity calculations. Furthermore, in-house 
compounds targeted IGF1R predicted by CRCPlatform were further validated by our 
collaborators, which indicate that our CRCPlatform is reliable for the CRC research. This 
online platform will be beneficial for the CRC research groups and bridge the gap between 
the biology and chemistry, enhance the efficiency of computer-aided drug design research 
process by finding the potential collaborators and employing existing data as well as 
computational technology. 
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6.0 FUTURE SPECULATIONS 	  	  
This thesis has discussed the CRCPlatform constructions and CRCPlatform tests were 
carried out in the form of case studies. Different types of chemogenomics tools such as 
TargetHunter, HTDocking imbedded in CRCPlatform are employed to find potential new 
targets. What’s more, the polypharmacology analysis is used to identify new targets and 
combination therapy for FDA-approved drugs for CRC.  Some of the FDA-approved drugs 
are already confirmed by the reported literature. In addition, our collaborator conducted 
experimental validations including MTS assays and apoptosis analysis for our in-house 
compounds. To further conduct CRC drug discovery research, there is still a long way to go. 
We will mainly summarize CRC research plan for the next stage as you can see below. 
 
1) Validation of our FDA approved drugs by experiments. We have proposed 
potentially new targets of FDA approved drugs for combination therapies or 
drug repurposing. For example, based on the polypharmacology analysis, 
Erlotinib with newly predicted targets including LDHB, HBB, CDK2, EPHX2; 
Sunitinib with newly predicted targets including PIM1, CDK2, EPHX2. Both 
of these two drugs share two similar targets CDK2 and EPHX2, implying that 
these two drugs may be combined together to improve their therapeutic effects. 
We still can find more anti-cancer drugs to determine more pairs of 
combination by applying polypharmcology analysis. Furthermore, high 
throughput screening assay of anti-cancer drug combination therapy might be 
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carried out to further confirm their improved effects predicted by our 
CRCPlatform.  
 
2) The new targets predictions by TargetHunter for natural compounds with anti-
CRC activities will be validated by potential collaborators found by Bioassay 
GeoMap imbedded in TargetHunter (See Table 5). We not only will test the 
natural compounds but also NCI database compounds by virtual screening. 
 
3) In-house compound XIE62-1034 inhibiting IGF1R related pathway analysis 
study might be carried out based on our hypothesis described in the discussion 
part by our potential collaborators. In addition, continuous spectrophotometric 
kinase assay may also be applied. Finally, if the results were good enough, we 
can further do research on IGF1R and our in-house compound XIE62-1034 co-
crystal. 
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APPENDIX ABBREVIATIONS 	  
15-PGDH 15-hydroxyprostaglandin dehydrogenase [NAD+]  
ABCG2 ATP-binding cassette sub-family G member 2  
ADBR2 Beta-2 adrenergic receptor 
ADME Absorption, distribution, metabolism, excretion 
AE Aloe Emodin 
AKT1 RAC-alpha serine/threonine-protein kinase  
ALB  Serum albumin 
APC Adenomatous polyposis coli  
ATIII Antithrombin-III 
BAX bcl-2-like protein 4 
BRAF Serine/threonine-protein kinase B-raf 
CBL Castitas B-lineage Lymphoma 
CDK2 Cyclin-dependent kinase 2 
CDK5 Cyclin-dependent kinase 5 
CIN Chromosomal Instability 
COMT Catechol O-methyltransferase  
COX-2 Prostaglandin-endoperoxide synthase 2 
CRC Colorectal Cancer 
CYP1A1 Cytochrome P450 1A1 
CYP1A2 Cytochrome P450 1A2 
CYP1B1 Cytochrome P450 1B1 
CYP2A6 Cytochrome P450 2A6 
CYP2C19 Cytochrome P450 2C19 
CYP2D6 Cytochrome P450 2D6 
CYP3A4 Cytochrome P450 3A4 
DPD Dihydropyrimidine dehydrogenase [NADP(+)]  
EDNRA Endothelin-1 receptor  
EGFR Epidermal growth factor receptor 
EPHA2 Ephrin type-A receptor 2 
EPHA2 Ephrin type-A receptor 2  
EPHX2 Cytosolic epoxide hydrolase 2 
ERBB2 Receptor tyrosine-protein kinase erbB-2 
FAP Familial adenomatous polyposis  
FGF2 Fibroblast growth factor 2 
GALE UDP-glucose 4-epimerase 
GCR Glucocorticoid receptor 
GI Gastrointestinal 
GPCR G protein coupled receptor 
GPU Grahphics processing unit 
GWAS Genome-wide association studies  
HSD11B1 Corticosteroid 11-beta-dehydrogenase isozyme 1 
HSP90 Heat shock protein (HSP) 90-alpha 
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IBD Inflammatory bowel diseases  
IGF1R Insulin-like growth factor 1 receptor 
IGF1R Insulin-like growth factor-1 receptor  
IL-1 Interleukin-1 
IL-6 Interleukin-6 
KCND2 Potassium voltage-gated channel subfamily D member 2  
KIT  Mast/stem cell growth factor receptor Kit  
KPCT Protein kinase C theta type 
KRAS V-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog  
LAP-1 Heat shock cognate 71 kDa protein 
MAPK Mitogen-activated protein kinase  
MMR DNA mismatch repair  
MSI Microsatellite Instability  
NCI National cancer institute 
NOS3 Nitric oxide synthase, endothelial 
NSCLC Non–small cell lung cancer  
NTRK1 High affinity nerve growth factor receptor 
PARP2 Poly [ADP-ribose] polymerase 2 
PBS Phosphate buffer solution 
PGE2 Prostaglandin E2  
PI3K Phosphoinositide 3’-kinase  
PLD phospholipase D 
PVDF Polyvinylidene Fluoride 
RTK Receptor tyrosine kinase 
SAR Structure-activity relationship  
SMILES Simplified molecular-input line-entry system 
Tdp1 Tyrosyl-DNA phosphodiesterase 1 
TNF-alpha Tumor necrosis factor (Cachectin) (TNF-alpha) 
TOP1 DNA topoisomerase 1 
TRAIL Tumor necrosis factor-related apoptosis-inducing ligand 
Trpv1 Transient receptor potential vanilloid type 1  
TYMS thymidylate synthetase 
VEGFR Vascular Endothelial Growth Factor Receptor 
   
	   62	  
 
BIBLIOGRAPHY 
 
1.     Brenner, H., M. Kloor, and C.P. Pox, Colorectal cancer. The Lancet. 383(9927): p.    
1490-1502. 
 
2.    Atkin, W.S., et al., Once-only flexible sigmoidoscopy screening in prevention of 
colorectal  cancer: a multicentre randomised controlled trial. Lancet, 2010. 
375(9726): p. 1624-33. 
 
3.         Siegel, R., et al., Cancer statistics, 2014. CA Cancer J Clin, 2014. 64(1): p. 9-29. 
 
4.       Howlader N, N.A., Krapcho M, et al., SEER Cancer Statistics Review, 1975-2010, 
2013. 
 
5.         NCI, General Information About Colon Cancer. 2014-05-12. 
 
6.      Slattery, M.L., et al., Diet, physical activity, and body size associations with rectal 
tumor mutations and epigenetic changes. Cancer Causes Control, 2010. 21(8): p. 
1237-45. 
 
7.     Sonnenberg, A. and R.M. Genta, Helicobacter pylori is a risk factor for colonic 
neoplasms. Am J Gastroenterol, 2013. 108(2): p. 208-15. 
 
8.     Kostic, A.D., et al., Genomic analysis identifies association of Fusobacterium with 
colorectal carcinoma. Genome Res, 2012. 22(2): p. 292-8. 
 
9.    Karsa, L.V., et al., The dimensions of the CRC problem. Best Pract Res Clin 
Gastroenterol, 2010. 24(4): p. 381-96. 
 
10.     Armour, B.S., et al., State-level prevalence of cigarette smoking and treatment advice, 
by disability status, United States, 2004. Prev Chronic Dis, 2007. 4(4): p. A86. 
 
11.    Comprehensive molecular characterization of human colon and rectal cancer. Nature, 
2012. 487(7407): p. 330-7. 
 
12.     Sadanandam, A., et al., A colorectal cancer classification system that associates 
cellular phenotype and responses to therapy. Nat Med, 2013. 19(5): p. 619-25. 
 
13.     Kinzler KW, V.B., Lessons from hereditary colorectal cancer. Cell, 1996(87): p. 159-
70. 
 
14.     Perea, J., et al., Early-onset colorectal cancer is an easy and effective tool to identify 
retrospectively Lynch syndrome. Ann Surg Oncol, 2011. 18(12): p. 3285-91. 
 
	   63	  
15.    Fearon, E.R., Molecular genetics of colorectal cancer. Annu Rev Pathol, 2011. 6: p. 
479-507. 
 
16.  Jass, J.R., Classification of colorectal cancer based on correlation of clinical, 
morphological and molecular features. Histopathology, 2007. 50(1): p. 113-30. 
 
17.     Silla, I.O., et al., Early-onset colorectal cancer: a separate subset of colorectal cancer. 
World J Gastroenterol, 2014. 20(46): p. 17288-96. 
 
18.     Vogelstein, B., et al., Cancer genome landscapes. Science, 2013. 340(6127): p. 1546-
1558. 
 
19.      Risio, M., The natural history of adenomas. Best Pract Res Clin Gastroenterol, 2010. 
24(3): p. 271-80. 
 
20.    Jones, S., et al., Comparative lesion sequencing provides insights into tumor evolution. 
Proc Natl Acad Sci U S A, 2008. 105(11): p. 4283-8. 
 
21.     Geiersbach, K.B. and W.S. Samowitz, Microsatellite instability and colorectal cancer. 
Arch Pathol Lab Med, 2011. 135(10): p. 1269-77. 
 
22.      Jass, J.R., J. Young, and B.A. Leggett, Evolution of colorectal cancer: change of pace 
and change of direction. J Gastroenterol Hepatol, 2002. 17(1): p. 17-26. 
 
23.    Leggett, B. and V. Whitehall, Role of the serrated pathway in colorectal cancer 
pathogenesis. Gastroenterology, 2010. 138(6): p. 2088-100. 
 
24.   Samadder, N.J., K. Jasperson, and R.W. Burt, Hereditary and Common Familial 
Colorectal Cancer: Evidence for Colorectal Screening. Dig Dis Sci, 2014. 
 
25.     Roy, H.K. and H.T. Lynch, Diagnosing Lynch syndrome: is the answer in the mouth? 
Gut, 2003. 52(12): p. 1665-7. 
 
26.    Rustgi, A.K., The genetics of hereditary colon cancer. Genes Dev, 2007. 21(20): p. 
2525-38. 
 
27.    Nielsen, M., et al., Germline mutations in APC and MUTYH are responsible for the 
majority of families with attenuated familial adenomatous polyposis. Clin Genet, 
2007. 71(5): p. 427-33. 
 
28.     Baserga, R., et al., The IGF-I receptor in cell growth, transformation and apoptosis. 
Biochim Biophys Acta, 1997. 1332(3): p. F105-26. 
 
29.     Butler, A.A., et al., Insulin-like growth factor-I receptor signal transduction: at the 
interface between physiology and cell biology. Comp Biochem Physiol B Biochem 
Mol Biol, 1998. 121(1): p. 19-26. 
 
30.    Reinmuth, N., et al., Blockade of insulin-like growth factor I receptor function inhibits 
growth and angiogenesis of colon cancer. Clin Cancer Res, 2002. 8(10): p. 3259-69. 
 
	   64	  
31.    Pollak, M., Insulin and insulin-like growth factor signalling in neoplasia. Nat Rev 
Cancer, 2008. 8(12): p. 915-28. 
 
32.    Chitnis, M.M., et al., The type 1 insulin-like growth factor receptor pathway. Clin 
Cancer Res, 2008. 14(20): p. 6364-70. 
 
33.     Chowdhury S, D.I., Sharratt E, Spernyak J, Brattain MG, et al., Anti-tumor Activity of 
IGF-1R Kinase Inhibitor PQIP in Colon Cancer. Clin Exp Pharmacol 2013. S4: 005. 
 
34.    Paul, S.M., et al., How to improve R&D productivity: the pharmaceutical industry's 
grand challenge. Nat Rev Drug Discov, 2010. 9(3): p. 203-14. 
 
35.    Rotella, D.P., Drug discovery 2012 and beyond. ACS Med Chem Lett, 2012. 3(3): p. 
172-3. 
 
36.    Lamb, J., et al., The Connectivity Map: using gene-expression signatures to connect 
small molecules, genes, and disease. Science, 2006. 313(5795): p. 1929-35. 
 
37.    Hindorff, L.A., et al., Potential etiologic and functional implications of genome-wide 
association loci for human diseases and traits. Proc Natl Acad Sci U S A, 2009. 
106(23): p. 9362-7. 
 
38.    Segal, E., et al., Module networks: identifying regulatory modules and their condition-
specific regulators from gene expression data. Nat Genet, 2003. 34(2): p. 166-76. 
 
39.   Hopkins, A.L., Network pharmacology: the next paradigm in drug discovery. Nat Chem 
Biol, 2008. 4(11): p. 682-90. 
 
40.    Boran, A.D. and R. Iyengar, Systems approaches to polypharmacology and drug 
discovery. Curr Opin Drug Discov Devel, 2010. 13(3): p. 297-309. 
 
41.     Peters, J.U., Polypharmacology - foe or friend? J Med Chem, 2013. 56(22): p. 8955-71. 
 
42.     Rask-Andersen, M., M.S. Almen, and H.B. Schioth, Trends in the exploitation of novel 
drug targets. Nat Rev Drug Discov, 2011. 10(8): p. 579-90. 
 
43.     Xie, X.Q., et al., Chemogenomics knowledgebased polypharmacology analyses of drug 
abuse related G-protein coupled receptors and their ligands. Front Pharmacol, 2014. 
5: p. 3. 
 
44.    Roth, B.L., D.J. Sheffler, and W.K. Kroeze, Magic shotguns versus magic bullets: 
selectively non-selective drugs for mood disorders and schizophrenia. Nat Rev Drug 
Discov, 2004. 3(4): p. 353-9. 
 
45.   Anighoro, A., J. Bajorath, and G. Rastelli, Polypharmacology: challenges and 
opportunities in drug discovery. J Med Chem, 2014. 57(19): p. 7874-87. 
 
46.    Liu, H., et al., AlzPlatform: an Alzheimer's disease domain-specific chemogenomics 
knowledgebase for polypharmacology and target identification research. J Chem Inf 
Model, 2014. 54(4): p. 1050-60. 
	   65	  
 
47.    Wang, L., et al., TargetHunter: an in silico target identification tool for predicting 
therapeutic potential of small organic molecules based on chemogenomic database. 
The AAPS journal, 2013. 15(2): p. 395-406. 
 
48.  O’Boyle, N.M., et al., Open Babel: An open chemical toolbox. Journal of 
Cheminformatics, 2011. 3(1): p. 1-14. 
 
49.    Ertl, P., Molecular structure input on the web. Journal of cheminformatics, 2009. 2(1): 
p. 1-9. 
 
50.    Wishart, D.S., et al., DrugBank: a knowledgebase for drugs, drug actions and drug 
targets. Nucleic acids research, 2008. 36(suppl_1): p. D901-D906. 
 
51.     Rédei, G.P., PubChem. 2008, Springer: New York. p. 1599. 
 
52.     National Cancer, I., Navigate the National Cancer Institute: cancer.gov. Vol. no. 03-
5008.; no. 03-5008. 2002, Bethesda, eBook: U.S. Dept. of Health and Human 
Services, National Institutes of Health, National Cancer Institute. 
 
53.    Ogata, H., et al., KEGG: Kyoto Encyclopedia of Genes and Genomes. Nucleic acids 
research, 1999. 27(1): p. 29-34. 
 
54.     Kanehisa, M., et al., The KEGG databases at GenomeNet. Nucleic acids research, 2002. 
30(1): p. 42-46. 
 
55.   Bento, A.P., et al., The ChEMBL bioactivity database: an update. Nucleic acids research, 
2013. 42(D1): p. D1083-D1090. 
 
56.      Buolamwini, J.K. and A.A. Adjei, Novel anticancer drug protocols. Vol. 85.; 85. 2003, 
Totowa, NJ: Humana Press. 
 
57.     Sandeep, G., et al., AUDocker LE: A GUI for virtual screening with AUTODOCK Vina. 
BMC research notes, 2011. 4(1): p. 445-445. 
 
58.     Wang, L., et al., TargetHunter: an in silico target identification tool for predicting 
therapeutic potential of small organic molecules based on chemogenomic database. 
Aaps j, 2013. 15(2): p. 395-406. 
 
59.   Kogej, T., et al., Multifingerprint based similarity searches for targeted class compound 
selection. J Chem Inf Model, 2006. 46(3): p. 1201-13. 
 
60.     Sun, Q., et al., Chemosensitization of head and neck cancer cells by PUMA. Mol 
Cancer Ther, 2007. 6(12 Pt 1): p. 3180-8. 
 
61.     Sun, Q., et al., Chemosensitization of head and neck cancer cells by PUMA. Mol 
Cancer Ther, 2007. 6(12): p. 3180-8. 
 
62.     Yu, J., et al., PUMA induces the rapid apoptosis of colorectal cancer cells. Mol Cell, 
2001. 7(3): p. 673-82. 
	   66	  
 
63.    Giovanella, B.C., et al., DNA Topoisomerase I-Targeted Chemotherapy of Human 
Colon Cancer in Xenografts. Science, 1989. 246(4933): p. 1046-1048. 
 
65.      Krause, D.S. and R.A. Van Etten, Tyrosine kinases as targets for cancer therapy. The 
New England journal of medicine, 2005. 353(2): p. 172-187. 
 
66.    Cancer Therapies; COX-2 Inhibitors Suppress Prostate Cancer Spread. Drug Week, 
2000: p. 13.14. 
 
67.     Barthélémy, P., et al., Pertuzumab: development beyond breast cancer. Anticancer 
Research, 2014. 34(4): p. 1483. 
 
68.       Frampton, J.E., Vandetanib. Drugs, 2012. 72(10): p. 1423. 
 
69.      Rini, B.I., Sorafenib. Expert opinion on pharmacotherapy, 2006. 7(4): p. 453-461. 
 
70.      Yu, Z., et al., Gemcitabine Adjuvant Therapy for Resected Pancreatic Cancer: A 
Meta-analysis. American Journal of Clinical Oncology, 2014: p. 1. 
 
71.    Miura, K., et al., The use of natural products in colorectal cancer drug discovery. 
Expert Opin Drug Discov, 2015: p. 1-16. 
 
72.    Prakash, O., et al., Anticancer Potential of Plants and Natural Products: A Review. 
American Journal of Pharmacological Sciences, 2013. 1(6): p. 104-115. 
 
73.    GU Zheng-bing, Y.G.-j., CONG Hai-ying, XU Yi-xin, CHEN Hai-sheng, ZHANG 
Wei-dong, Studies on chemical constituents from root of Patrinia scabra. Chinese 
Traditional and Herbal Drugs, 2002. 09. 
 
74.    Aly, A.H., et al., NF kappa B inhibitors and antitrypanosomal metabolites from 
endophytic fungus Penicillium sp. isolated from Limonium tubiflorum. Bioorg Med 
Chem, 2011. 19(1): p. 414-21. 
 
75.     Elzner, S., et al., Inhibitors of inducible NO synthase expression: total synthesis of (S)-
curvularin and its ring homologues. ChemMedChem, 2008. 3(6): p. 924-39. 
 
76.   Schmidt, N., et al., Transcriptional and post-transcriptional regulation of iNOS 
expression in human chondrocytes. Biochem Pharmacol, 2010. 79(5): p. 722-32. 
 
77.    Eshun, K. and Q. He, Aloe vera: a valuable ingredient for the food, pharmaceutical and 
cosmetic industries--a review. Crit Rev Food Sci Nutr, 2004. 44(2): p. 91-6. 
 
78.     Lin, M.L., et al., Aloe-emodin induces apoptosis of human nasopharyngeal carcinoma 
cells via caspase-8-mediated activation of the mitochondrial death pathway. Cancer 
Lett, 2010. 291(1): p. 46-58. 
 
79.      Lin, K.Y. and Y.H. Uen, Aloe-emodin, an anthraquinone, in vitro inhibits 
proliferation and induces apoptosis in human colon carcinoma cells. Oncol Lett, 
2010. 1(3): p. 541-547. 
	   67	  
 
80.     Lee, H.Z., et al., Effects and mechanisms of aloe-emodin on cell death in human lung 
squamous cell carcinoma. Eur J Pharmacol, 2001. 431(3): p. 287-95. 
 
81.    Pecere, T., et al., Aloe-emodin is a new type of anticancer agent with selective activity 
against neuroectodermal tumors. Cancer Res, 2000. 60(11): p. 2800-4. 
 
82.    Suboj, P., et al., Aloe emodin inhibits colon cancer cell migration/angiogenesis by 
downregulating MMP-2/9, RhoB and VEGF via reduced DNA binding activity of NF-
kappaB. Eur J Pharm Sci, 2012. 45(5): p. 581-91. 
 
83.   Weidlich, I.E., et al., Inhibitors of human tyrosyl-DNA phospodiesterase (hTdp1) 
developed by virtual screening using ligand-based pharmacophores. Bioorg Med 
Chem, 2010. 18(1): p. 182-9. 
 
84.     Walker, S., et al., Development of an oligonucleotide-based fluorescence assay for the 
identification of tyrosyl-DNA phosphodiesterase 1 (TDP1) inhibitors. Anal Biochem, 
2014. 454: p. 17-22. 
 
85.    Krell, J., et al., Growth Arrest-Specific Transcript 5 Associated snoRNA Levels Are 
Related to p53 Expression and DNA Damage in Colorectal Cancer. PLoS One, 2014. 
9(6): p. e98561. 
 
86.    Dexheimer, T.S., et al., Tyrosyl-DNA phosphodiesterase as a target for anticancer 
therapy. Anticancer Agents Med Chem, 2008. 8(4): p. 381-9. 
 
87.      Kang, P.S., et al., Prognostic implication of 15-hydroxyprostaglandin dehydrogenase 
down-regulation in patients with colorectal cancer. J Korean Soc Coloproctol, 2012. 
28(5): p. 253-8. 
 
88.     Tai, H.H., et al., NAD+-linked 15-hydroxyprostaglandin dehydrogenase: structure and 
biological functions. Curr Pharm Des, 2006. 12(8): p. 955-62. 
 
89.    Rigas, B., I.S. Goldman, and L. Levine, Altered eicosanoid levels in human colon 
cancer. J Lab Clin Med, 1993. 122(5): p. 518-23. 
 
90.    Sirivolu, V.R., et al., 5-Arylidenethioxothiazolidinones as inhibitors of tyrosyl-DNA 
phosphodiesterase I. J Med Chem, 2012. 55(20): p. 8671-84. 
 
91.     Nguyen, T.X., et al., Synthesis and biological evaluation of the first dual tyrosyl-DNA 
phosphodiesterase I (Tdp1)-topoisomerase I (Top1) inhibitors. J Med Chem, 2012. 
55(9): p. 4457-78. 
92.     Martin, Y.C., J.L. Kofron, and L.M. Traphagen, Do structurally similar molecules have 
similar biological activity? J Med Chem, 2002. 45(19): p. 4350-8. 
 
93.    Heikamp, K. and J. Bajorath, Large-scale similarity search profiling of ChEMBL 
compound data sets. J Chem Inf Model, 2011. 51(8): p. 1831-9. 
 
94.     Dean, R.A., et al., Identification of a putative Tdp1 inhibitor (CD00509) by in vitro and 
cell-based assays. J Biomol Screen, 2014. 19(10): p. 1372-82. 
	   68	  
 
95.    Matsumoto, K., et al., Localization of TRPV1 and contractile effect of capsaicin in 
mouse large intestine: high abundance and sensitivity in rectum and distal colon. Am 
J Physiol Gastrointest Liver Physiol, 2009. 297(2): p. G348-60. 
 
96.     Karin, M. and F.R. Greten, NF-kappaB: linking inflammation and immunity to cancer 
development and progression. Nat Rev Immunol, 2005. 5(10): p. 749-59. 
 
97.     Sung, B., et al., Capsazepine, a TRPV1 antagonist, sensitizes colorectal cancer cells to 
apoptosis by TRAIL through ROS-JNK-CHOP-mediated upregulation of death 
receptors. Free Radic Biol Med, 2012. 53(10): p. 1977-87. 
 
98.    Prevarskaya, N., L. Zhang, and G. Barritt, TRP channels in cancer. Biochimica et 
Biophysica Acta (BBA) - Molecular Basis of Disease, 2007. 1772(8): p. 937-946. 
 
99.   Domotor, A., et al., Immunohistochemical distribution of vanilloid receptor, calcitonin-
gene related peptide and substance P in gastrointestinal mucosa of patients with 
different gastrointestinal disorders. Inflammopharmacology, 2005. 13(1-3): p. 161-77. 
 
100.  Ahern, G.P., X. Wang, and R.L. Miyares, Polyamines are potent ligands for the 
capsaicin receptor TRPV1. J Biol Chem, 2006. 281(13): p. 8991-5. 
 
101.  Long, S.B., et al., Atomic structure of a voltage-dependent K+ channel in a lipid 
membrane-like environment. Nature, 2007. 450(7168): p. 376-82. 
 
102.    Feng, Z., et al., Structural Insight into Tetrameric hTRPV1 from Homology Modeling, 
Molecular Docking, Molecular Dynamics Simulation, Virtual Screening and Bioassay 
Validations. J Chem Inf Model, 2015. 
 
103.   Li, W., et al., Kaempferol induces apoptosis in human HCT116 colon cancer cells via 
the Ataxia-Telangiectasia Mutated-p53 pathway with the involvement of p53 
Upregulated Modulator of Apoptosis. Chem Biol Interact, 2009. 177(2): p. 121-7. 
 
104.    Chahar, M.K., et al., Flavonoids: A versatile source of anticancer drugs. Pharmacogn 
Rev, 2011. 5(9): p. 1-12. 
 
105.   Wang, J., et al., Discovery and bioactivity of 4-(2-arylpyrido[3',2':3,4]pyrrolo[1,2-
f][1,2,4]triazin-4-yl) morpholine derivatives as novel PI3K inhibitors. Bioorg Med 
Chem Lett, 2012. 22(1): p. 339-42. 
 
106.     Deeks, E.D. and E. Raymond, Sunitinib. BioDrugs, 2011. 25(5): p. 307. 
 
107.     Lyseng-Williamson, K.A., Erlotinib. Molecular Diagnosis & Therapy, 2013. 17(1): p. 
57. 
 
108.    Levitzki, A., Tyrosine kinase inhibitors: views of selectivity, sensitivity, and clinical 
performance. Annu Rev Pharmacol Toxicol, 2013. 53: p. 161-85. 
 
109.  Davis, M.I., et al., Comprehensive analysis of kinase inhibitor selectivity. Nat 
Biotechnol, 2011. 29(11): p. 1046-51. 
	   69	  
 
110.  van Erp, N.P., H. Gelderblom, and H.J. Guchelaar, Clinical pharmacokinetics of 
tyrosine kinase inhibitors. Cancer Treat Rev, 2009. 35(8): p. 692-706. 
 
111.   Li, J., et al., Differential metabolism of gefitinib and erlotinib by human cytochrome 
P450 enzymes. Clin Cancer Res, 2007. 13(12): p. 3731-7. 
 
112.  Teng, W.C., et al., Mechanism-based inactivation of cytochrome P450 3A4 by lapatinib. 
Mol Pharmacol, 2010. 78(4): p. 693-703. 
 
113.  Lorenzen, S., et al., Lapatinib versus lapatinib plus capecitabine as second-line 
treatment in human epidermal growth factor receptor 2-amplified metastatic gastro-
oesophageal cancer: A randomised phase II trial of the Arbeitsgemeinschaft 
Internistische Onkologie. Eur J Cancer, 2015. 
 
114.  Abrams, T.J., et al., SU11248 inhibits KIT and platelet-derived growth factor receptor 
beta in preclinical models of human small cell lung cancer. Mol Cancer Ther, 2003. 
2(5): p. 471-8. 
 
115.  Sotelo, M.J., et al., Lapatinib plus trastuzumab in pretreated human epidermal growth 
factor receptor 2-positive metastatic breast cancer. J Cancer Res Ther, 2014. 10(4): p. 
967-72. 
 
116.   Cai, J., et al., Design and synthesis of novel 4-benzothiazole amino quinazolines 
Dasatinib derivatives as potential anti-tumor agents. Eur J Med Chem, 2013. 63: p. 
702-12. 
 
117.   Wu, X., et al., Design and synthesis of novel Gefitinib analogues with improved anti-
tumor activity. Bioorg Med Chem, 2010. 18(11): p. 3812-22. 
 
118.   Usui, T., et al., Discovery of indenopyrazoles as EGFR and VEGFR-2 tyrosine kinase 
inhibitors by in silico high-throughput screening. Bioorg Med Chem Lett, 2008. 18(1): 
p. 285-8. 
 
119.   Hottecke, N., et al., Inhibition of gamma-secretase by the CK1 inhibitor IC261 does 
not depend on CK1delta. Bioorg Med Chem Lett, 2010. 20(9): p. 2958-63. 
 
120.   Levkowitz, G., et al., Ubiquitin Ligase Activity and Tyrosine Phosphorylation Underlie 
Suppression of Growth Factor Signaling by c-Cbl/Sli-1. Molecular Cell, 1999. 4(6): p. 
1029-1040. 
 
121.  Lind, J.S.W., et al., A multicenter phase II study of erlotinib and sorafenib in 
chemotherapy-naive patients with advanced non-small cell lung cancer. Clinical 
cancer research : an official journal of the American Association for Cancer Research, 
2010. 16(11): p. 3078-3087. 
 
122.  Yang, B.L., et al., [Effects of Baicalin on an orthotopic transplantation mouse model of 
mismatch repair gene deficient colorectal cancer]. Zhonghua Wai Ke Za Zhi, 2012. 
50(9): p. 843-7. 
 
	   70	  
123.  Duran, I., et al., Phase I targeted combination trial of sorafenib and erlotinib in patients 
with advanced solid tumors. Clinical cancer research : an official journal of the 
American Association for Cancer Research, 2007. 13(16): p. 4849-4857. 
 
124.  Lane, D., Designer combination therapy for cancer. Nature biotechnology, 2006. 24(2): 
p. 163-164. 
 
125.  Abera, M.B. and M.G. Kazanietz, Protein Kinase C Alpha Mediates Erlotinib 
Resistance in Lung Cancer Cells. Mol Pharmacol, 2015. 
 
126.  Trujillo, J.I., et al., 2-(6-Phenyl-1H-indazol-3-yl)-1H-benzo[d]imidazoles: design and 
synthesis of a potent and isoform selective PKC-zeta inhibitor. Bioorg Med Chem 
Lett, 2009. 19(3): p. 908-11. 
 
127.  LeRoith, D. and C.T. Roberts, Jr., The insulin-like growth factor system and cancer. 
Cancer Lett, 2003. 195(2): p. 127-37. 
 
128.   Yu, J., et al., PUMA mediates the apoptotic response to p53 in colorectal cancer cells. 
Proc Natl Acad Sci U S A, 2003. 100(4): p. 1931-6. 
 
129.  Zhang, L. and J. Yu, Role of apoptosis in colon cancer biology, therapy, and prevention. 
Curr Colorectal Cancer Rep, 2013. 9(4). 
 
130.   Cunningham, D., et al., Colorectal cancer. The Lancet, 2010. 375(9719): p. 1030-1047. 
 
131.   Liu, R.Z., et al., Abstract B94: An integrated database in colorectal cancer outcomes, 
prognosis, and epidemiology (The COPE database). Cancer Prevention Research, 
2010. 3(12 Supplement): p. B94-B94. 
 
132.  Harling, H., 146. Danish colorectal cancer database – Items in the audit. European 
Journal of Surgical Oncology (EJSO), 2012. 38(9): p. 781. 
 
133.   Anonymous, Maven Semantic: Colorectal Cancer Research Database Update11-01-
25&rft.pub=Business+Wire&rft.externalDocID=2247843681&paramdict=en-US U7 
- Newspaper Article. 2011, Business Wire: New York. 
 
134. Dias, K.S. and C. Viegas, Jr., Multi-Target Directed Drugs: A Modern Approach for 
Design of New Drugs for the treatment of Alzheimer's Disease. Curr Neuropharmacol, 
2014. 12(3): p. 239-55. 
 
